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Abstract 
Alkaloids are naturally occurring nitrogen containing biologically active 
heterocyclic compounds. Over the last years, a large number of 
biologically alkaloids with antiviral, antibacterial, anti-inflammatory, 
antimalarial, antioxidant and anticancer activities have been isolated from 
marine source. 
In this frame parazoanthines are a group of unique naturally-occurring 
marine alkaloids reported to date only from the Mediterranean sea 
anemone Parazoanthus axinellae. The chemical framework characteristic 
of these molecules is a 3,5-alkyl disubstituted hydantoin core bearing a 
terminal guanidine and an aromatic ring. Hydantoins and derivatives have 
been widely used in biomedical studies including novel therapeutic agents 
of interest as anti-convulsants and antimuscarinics,antiulcers and 
antiarrythmics, antivirals, antidiabetics, and inhibitors of antagonist of 
serotonin and fibrinogen receptors, inhibitors of glycine binding site of the 
NMDA receptor and antagonists of leukocyte cell adhesion. 
Due to the biological potential of this class of molecules, a synthetic 
strategy was planed and developed to prepare natural and not natural 
analogs of parazoanthines; the molecular docking tests have described a 
promising antagonist activity on co-chemokine receptor CXCR4, involved 
in many tumors (breast cancer, melanoma, leukemia multiple myeloma, 
small cell lung cancer (SCLC), malignant melanoma and pancreatic cancer), 
rheumatoid arthritis, stem cell mobilization and HIV-1.  
The preliminary tests in vitro have confirmed the antagonist effect of 
parazoanthine-A with the co-receptor CXCR4, describing a promising 
pharmacological action for the treatment of diseases involved by the 
activation of this receptor. 
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Chapter I 
 
1 Alkaloids 
 
Alkaloids are a group of naturally occurring chemical compounds that 
mostly contain basic nitrogen atoms. This group also includes some 
related compounds with neutral and even weakly acidic properties. Some 
synthetic compounds of similar structure are also termed alkaloids.1 In 
addition to carbon, hydrogen and nitrogen, alkaloids may also 
contain oxygen, sulfur and, more rarely, other elements such 
as chlorine, bromine, and phosphorus. They are produced by a large 
variety of organisms including bacteria, fungi, plants, and animals. Millions 
of people around the Globe use purine alkaloids every day as well as 
starting the day with a cup of coffee or drinking a cup of tea in the 
afternoon. Alkaloids are molecules participating in both producer and 
consumer chains in nature and they are vital in feeding, and enjoy 
servations, agressivity and defence for all living species. 1 
The alkaloids content in plants is usually within a few percent and is 
inhomogeneous over the plant tissues. Depending on the type of plants, 
the maximum concentration is observed in the leaves (black 
henbane), fruits or seeds (Strychnine tree), root (Rauwolfia serpentina) or 
                                                          
1 Aniszewski, Tadeusz Alkaloids – secrets of life. 2007 Amsterdam: Elsevier  p.1 
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bark (cinchona).2 Furthermore, different tissues of the same plants may 
contain different alkaloids.3 
Beside plants, alkaloids are found in certain types of fungi, such 
as psilocybin in the fungus of the genus Psilocybe, and in animals, such 
as bufotenin in the skin of some toads. Some amines, such 
as adrenaline and serotonin, which play an important role in higher 
animals, are similar to alkaloids in their structure and biosynthesis and are 
sometimes called alkaloids.4 Alkaloids were usually found from marine 
organisms also.1  
 Alkaloids classification 1.1
Compared with most other classes of natural compounds, alkaloids are 
characterized by a great structural diversity and there is no uniform 
classification of alkaloids. For the biologist, they are a pure and perfect 
natural products.  
From the biological point of view, the alkaloid is any biologically active and 
heterocyclic chemical compound which contains nitrogen and could have 
some pharmacological activity and, in many cases, medicinal or ecological 
use. 5 For the medical scientist, the term “alkaloids” means any group of 
nitrogenous substances of vegetable origin, often of complex structure 
and high molecular mass. Medicine focuses on physiological action of 
alkaloids used as curative drugs. Some of these compounds can also be 
                                                          
2 Grinkevich NI Safronich LN. The chemical analysis of medicinal plants: Proc. allowance for 
pharmaceutical universities. 1983 p.122-123 
3 Orekhov, AP. Chemistry alkaloids (Acad. 2 ed.). 1955  p.12 
4 Aniszewski, Tadeusz. Alkaloids – secrets of life. 2007 Amsterdam: Elsevier  P.110-111 
5
 Aniszewski, T.. The biological basis of quinolizidine alkaloids. Science of Legumes, 1994 1: 1–24 
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highly toxic, even in very small doses. 6 Alkaloids can be classified in the 
terms of their: biological and ecological activity;  chemical structures and 
biosynthetic pathway, but they are generally classified by their common 
molecular precursors, based on the biological pathway used by nature to 
build the molecule. From a structural point of view, alkaloids are divided 
according to their shapes and origins. There are three main types of 
alkaloids:  
I. true alkaloids  
II. protoalkaloids 
III. pseudoalkaloids. 
True alkaloids and protoalkaloids are derived from amino acids, whereas 
pseudoalkaloids are not (Table 1). 7 
  
                                                          
6 Lovell Becker, E., Butterfield, W. J. H., McGehee Harvey, A., Heptinstall, R. H. and Lewis, T. (eds). 
International Dictionary of Medicine and Biology. 1986 New York: John Wiley & Sons. 
7 Aniszewski, Tadeusz. Alkaloids – secrets of life. 2007 Amsterdam: Elsevier  P.6-10 
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ALKALOID 
TYPE 
PRECURSOR 
COMPOUND 
CHEMICAL 
GROUP OF 
ALKALOIDS 
EXAMPLES OF 
ALKALOIDS 
True 
Alkaloids 
L-ornithine   
 
 
 
Pyrrolidine 
alkaloids 
 
 
Hygrine 
Cuscohygrine 
  
Tropane alkaloids 
 
 
Atropine 
Cocaine 
Hyoscyamine 
Scopolamine/ 
hyoscine 
  
 
Pyrrolizidine 
alkaloids 
 
 
 
Acetyllycopsamine 
Acetyl-intermedine 
Europine 
Homospermidine 
Ilamine 
Indicine-N-oxide 
Meteloidine 
Retronecine 
 
L-lysine  
 
 
 
 
 
Piperidine 
alkaloids 
 
 
Anaferine 
Lobelanine 
Lobeline 
N-methyl pelletierine 
Pelletierine 
Piperidine 
Piperine 
Pseudopelletierine 
Sedamine 
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Quinolizidine 
alkaloids 
 
 
Cytisine 
Lupanine 
Sparteine 
  
 
Indolizidine 
alkaloids 
 
 
 
Castanospermine 
Swansonine 
 L-tyrosine   
 
 
 
 
Phenylethylamino 
alkaloids 
 
 
 
Adrenaline 
Anhalamine 
Dopamine 
Noradrealine 
Tyramine 
  
 
Simple 
tetrahydroisoquin
oline alkaloids 
 
 
 
 
Codeine 
Morphine 
Norcoclaurine 
Papaverine 
Tetrandrine 
Thebaine 
Tubocurarine 
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L-tyrosine 
or 
L-phenylanine 
 
  
 
 
 
Phenethylisoquin
oline alkaloids 
Autumnaline 
Crinine 
Floramultine 
Galanthamine 
Galanthine 
Haemanthamine 
Lycorine 
Lycorenine 
Maritidine 
Oxomaritidine 
Vittatine 
 L-tryptophan   
 
 
 
Indole alkaloids 
 
 
Arundacine 
Arundamine 
Psilocin 
Serotonin 
Tryptamine 
Zolmitriptan 
Harmine 
Elaeagnine 
Ajmalicine 
Catharanthine 
Secologanin 
Tabersonine 
  
 
Quinoline 
alkaloids 
 
 
Chloroquinine 
Cinchonidine 
Quinine 
Quinidine 
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Pyrroloindole 
alkaloids 
 
 
 
 
A-yohimbine 
Chimonantheine 
Chimonantheine 
Corynantheine 
Corynantheidine 
Dihydrocorynanthein
e Corynanthine 
  Ergot alkaloids 
Ergobine 
Ergotamine 
Ergocryptine 
 L-histidine   
 
 
 
 
Imidazole 
alkaloids 
 
 
 
Histamine 
Pilocarpine 
Pilosine 
  
 
Manzamine 
alkaloids 
Xestomanzamine A 
Xestomanzamine B 
 L-arginine   
 
 
 
Marine alkaloids 
Saxitoxin 
Tetrodotoxin 
Parazoanthine 
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 Antranilic acid   
 
 
 
Quinazinoline 
alkaloids 
 
 
 
Peganine 
  
Quinoline 
alkaloids 
 
 
 
 
Acetylfolidine 
Acutine Bucharine 
Dictamnine 
Dubunidine 
Flindersine 
Foliosidine 
Glycoperine 
Haplophyllidine 
Haplopine Helietidine 
Kokusaginine 
Maculosine 
Perfamine Perforine 
Polifidine 
Skimmianine 
 
  
 
Acridone 
alkaloids 
 
 
 
Acronycine 
Rutacridone 
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 Nicotinic Acid   
 
 
Pyridine alkaloids 
 
 
 
Anabasine 
Cassinine 
Celapanin 
Evoline 
Evonoline 
Evorine 
Maymyrsine 
Nicotine 
Regelidine 
Wilforine 
 
Proto- 
alkaloids 
L-tyrosine   
 
 
 
Phenylethylamino 
alkaloids 
 
 
 
Hordenine 
Mescaline 
 L-tryptophan   
 
 
 
Terpenoid indole 
alkaloids Yohimbine 
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 L-ornithine   
 
 
Pyrrolizidine 
alkaloids 
 
 
 
4-hydroxystachydrine 
Stachydrine 
Pseudo- 
alkaloids 
Acetate   
 
 
Piperidine 
alkaloids 
 
 
 
Coniine 
Coniceine 
Pinidine 
  
Sesquiterpene 
alkaloids 
Cassinine 
Celapanin 
Evonine 
Evonoline 
Evorine 
Maymyrsine 
Regelidine 
Wilforine 
 Pyruvic acid   
 
 
Ephedra alkaloids 
Cathine 
Cathinone 
Ephedrine 
Norephedrine 
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Table 1. Main types of alkaloids and their chemical groups 
 Ferulic acid   
 
 
Aromatic  
alkaloid 
Capsaicin 
 
 Geraniol   
 
 
Terpenoid 
alkaloid 
Aconitine 
Actinidine 
Atisine 
Gentianine 
 Saponins   
 
                                                                                                                             
(es. digitonin) 
Steroid alkaloids 
Cholestane 
Conessine 
Cyclopamine 
Jervine Pregnenolone 
Protoveratrine A 
Protoveratrine B 
Solanidine 
Solasodine 
Squalamine 
Tomatidine 
 Adenine/ Guanine   
  
 
Purine alkaloids 
Caffeine 
Theobromine 
Theophylline 
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1.1.1 True alkaloids 
True alkaloids derive from aminoacids and they share an heterocyclic ring 
with nitrogen. The non-nitrogen containing rings or side chains are derived 
from terpene units and / or acetate, while methionine is responsible for 
the addition of methyl groups to nitrogen atoms. These alkaloids are 
highly reactive substances with biological activity even in low doses. All 
true alkaloids have a bitter taste and appear as a white solid, with the 
exception of nicotine which has a brown color. True alkaloids form water-
soluble salts. Moreover, most of them are well-defined crystalline 
substances which reacts with acids to form salts. True alkaloids may occur 
in plants in the free state, as salts and as N-oxides. These alkaloids occur in 
a limited number of species and families, and are those compounds in 
which decarboxylated amino acids are condensed with a non-nitrogenous 
structural moiety. The primary precursors of true alkaloids are such amino 
acids as L-ornithine, L-lysine, L-phenylalanine/L-tyrosine, L-tryptophan and 
L-histidine.8 Examples of true alkaloids include such biologically active 
alkaloids as cocaine (Figure 1A), quinine, dopamine (Figure 1B), morphine 
and usambarensine. More examples appears in Table 1. 
 
                          
(A)      (B) 
 
Figure 1. Cocaine (A), Dopamine (B) 
                                                          
8 Dewick, P. M.. Medicinal Natural Products. A Biosynthetic Approach. Second Edition. 2002 Chichester – 
New York: John Wiley & Sons Ltd 
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1.1.2 Protoalkaloids 
Protoalkaloids are compounds, in which the N atom derived from an 
amino acid is not a part of the heterocycle. 9 
Such kinds of alkaloid include compounds derived from L-tyrosine and L-
tryptophan (see Table 1). They form a minority of all alkaloids. Hordenine, 
mescaline (Figure 2A) and yohimbine are examples of these kinds of 
alkaloid. 10 
Chini et al.11 have found new alkaloids, stachydrine (Figure 2B) and 4-
hydroxystachydrine, derived from Boscia angustifolia, a plant belonging to 
the Capparidacea family. These alkaloids have a pyrroline nucleus and are 
basic alkaloids in the genus Boscia. The species from this genus have been 
used in folk medicine in East and South Africa. Boscia angustifolia is used 
for the treatment of mental illness, and occasionally to combat pain and 
neuralgia. 
 
                                     
   (A)      (B) 
 
Figure 2. Mescaline (A), Stachydrine (B)  
 
                                                          
9
 Jakubke, H.-D., Jeschkeit, H. and Eagleson, M. Concise Encyklopedia Chemistry. 1994 Berlin – New 
York: Walter de Gruyter 
10 Chini, C., Bilia, A. R., Keita, A. and Morelli, I. Planta Medica, 1992 58: 476 
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1.1.3 Pseudoalkaloids 
In this class of compounds the basic carbon skeletons are not derived from 
aminoacids. 11 Furthermore, pseudoalkaloids are connected with 
aminoacids pathways. They are derived from the precursors or 
postcursors (derivatives from degradation processes) of aminoacids. They 
can also result from the amination and transamination reactions12 of the 
different pathways connected with precursors or postcursors of 
aminoacids. These alkaloids can also be derived from non-aminoacid 
precursors. The N atom is inserted into the molecule at a relatively late 
stage as in the case of steroidal or terpenoid skeletons. The N atom can 
also be donated by an aminoacidic source across a transamination 
reaction, if there is a suitable aldehyde or ketone. Pseudoalkaloids can be 
acetate and phenylalanine derived or terpenoid, as well as steroidal 
alkaloids. Examples of pseudoalkaloids include such compounds as 
coniine, capsaicin, ephedrine (Figure 3A), solanidine (Figure 3B), caffeine, 
theobromine and pinidine. More examples appear in Table 1.    
                                                  
(A)                                                                      (B) 
 
                                                          
11 Jakubke, H.-D., Jeschkeit, H. and Eagleson, M. Concise Encyklopedia Chemistry. 1994 Berlin – New 
York: Walter de Gruyter 
12 Dewick, P. M. Medicinal Natural Products. A Biosynthetic Approach. Second Edition. 2002 Chichester – 
New York: John Wiley & Sons Ltd 
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Figure 3. Ephedrine (A), Solanidine (B) 
 Biogenesis of alkaloids 1.2
The synthesis and structural analysis of alkaloids leads to the following 
basic questions: why are alkaloids synthesized in an organism? It is known 
that alkaloids have a genetic nature13 and the alkaloid content is diverse 
inside and between the species.14 In nature the same species of plants 
may have both high and low alkaloid content. 15, 16 Natural hybridization 
has been successfully used in plant breeding for the development of the 
so-called “sweetcultivars” in crop production. In “Sweet cultivars”, 
however, alkaloids are present and their total removal is not possible. 
“Sweet cultivars” are therefore plants, in which alkaloids are present at a 
very low level and the bioactivity of which is not of any significant or 
observable level. However, alkaloid decrease by hybridization is an 
undirect but strong argument for the case that alkaloids have an natural 
heredity and that their presence in plants has an evolutionary meaning. 
This is fundamental in doing the first question connected with the 
biogenesis of alkaloids. Alkaloids have a strong genetic–physiological 
function in the organisms which produce them. The biogenesis of alkaloids 
is therefore a part of the total genetic-functional strategy of such 
metabolisms. 
 
 
                                                          
13 Nowacki, E. "Inheritance and biosynthesis of alkaloids in lupin." Genetica Polonica 4.2 1963: 161-202. 
14 Waller, G. R., and E. K. Nowacki. "Alkaloid biology and metabolism in plants Plenum Press." New 
York 1978: 294. 
15Aniszewski, T. Lupine/a potential crop in Finland/studies on the ecology, productivity, and quality of 
Lupinus spp. 1993 University of Joensuu: p.148 
16 Aniszewski, T. Lupine/a potential crop in Finland/studies on the ecology, productivity, and quality of 
Lupinus spp. 1993 University of Joensuu, 29: 1–50 
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 Chemistry models 1.3
Since the year 1805, when alkaloid chemical research started, the topic 
regarding the biogenesis of alkaloids proved central for chemists. The 
background to this argument was the fact that chemical compounds are 
synthesized by plants, used by plants and degradaded by plants. In the 
case of alkaloids, it was still difficult in the middle of the 20th century to 
truly ascertain the purpose of alkaloids in plants. Certainly, the use of 
these compounds in many applications outside of the organisms 
producing them was well recognized but their role within the plants, 
especially in the metabolism, was not known. The general thinking was 
that alkaloids were “the waste” product of metabolisms and had no active 
role to play. Therefore, chemical cycle of alkaloid production were 
explained as chemical reactions, the “technical” process of life. Later, 
especially since the late 70s of the 20th century, the theory of “wastes” 
was debated and corrected.17 However, chemical research has now 
extensively proved the existence of new alkaloids, the pathways of their 
biosynthesis and structural modification. Three directions in this research 
have been followed, one purely chemical, the second, biochemical, and 
the third purely biomolecular, or the molbiological direction. The chemical 
explanation of alkaloid biogenesis is based on the consideration that all 
reactions are of a chemical nature and that the energy needed for life is 
produced by chemical reactions. 
 
                                                          
17 Waller, G. R., and E. K. Nowacki. "Alkaloid biology and metabolism in plants Plenum Press." New 
York 1978, 294. 
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Figure 4. Chemical explanation for alkaloid biogenesis in organisms (c=catalysers). 
 
Figure 4 shows a diagram of the chemical explanations for alkaloid 
biogenesis, from which it’s clear that alkaloids are some of metabolic 
objects in the living organisms. It has a long chemical cycle, which includes 
synthesis before and degradation after its functional activity in the 
metabolism. Biogenesis is, therefore, considered by chemistry to be the 
chain of the reactions between molecules favoured by particular 
conditions and catalysers of special importance. Different alkaloids have 
their own biogenesis that are inspiration source for biochemical models 
and for developing new methods for synthetic reactions and structural 
modifications. Moreover, these models are also used in biotechnology. 
18,19 
 
                                                          
18 Robins, R. J., Parr, A. J. and Walton, N. J. Planta, 1991 183: 196–201 
19 Robins, R. J., Parr, A. J. and Walton, N. J. Planta, 1991 183: 185–195 
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 Biochemistry models 1.4
The description of single enzyme activity in chemical reactions, together 
with the activity of other biomolecules, is typical for biochemical models 
of alkaloids biogenesis. There is no contradiction between chemical and 
biochemical, which enrich each other. In many cases, typical chemical and 
biochemical models are unified in many papers nowadays.19,20 Biochemical 
reactions are basically the same as other chemical organic reactions with 
their thermodynamic and mechanistic characteristics, but they have the 
enzymatic step. Thermodynamic laws, standard energy status and 
standard free energy change, reduction–oxidation (redox) and 
electrochemical potential equations are applicable to these reactions. 
Enzymes catalyse reactions and induce them to be much faster. 20,21 
The biochemical models are subject to both qualitative and quantitative 
alkaloid analysis. Not all enzymes participating in alkaloid synthesis and 
degradation are yet known. Alkaloid enzymatology is, therefore, a growing 
research area 
 
 Molecular biology models 1.5
Alkaloid research and bioanalysis of central-processing molecules (DNA 
and RNA) led to the important concept of the natural heredity of alkaloids 
metabolism. Recent investigations have proved empirically that alkaloids 
                                                          
20 Torssell, K. B. G. Natural Product Chemistry. A Mechanistic and Biosynthetic Approach to Secondary 
Metabolism. 1983 Chichester – New York – Brisbane – Toronto – Singapore: John Wiley & Sons Limited 
21 Wilson, Keith, and John Walker. Principles and techniques of practical biochemistry. Cambridge 
University Press, 2000, pp. 357–402 
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have a genetic background and that all their biogenesis is genetically 
determined. 22, 23, 24, 25, 26 
According to Tudzynski et al.27, cpd1 gene coding for 
dimethylallyltryptophan syntase (DMATS) catalyses the first step in the 
biosynthesis of ergot alkaloids from Claviceps purpurea. 
This means that detailed molecular genetic analysis of the alkaloid 
pathway is possible.27 These results were confirmed by the research of 
Haarmann et al.24 Moreover, Huang and Kutchan26 found three genes 
(cyp80b1, bbe1 and cor1) which encode the enzymes needed for 
sanguinarine synthesis. 
Molecular biology research on alkaloids is very revealing and its results 
can be used in the construction of alkaloid biogenetic models. At present, 
only a few alkaloid metabolism genes are known. 
 
 Biosynthesis and metabolism 1.6
Alkaloids are derived from the aminoacid in L-configuration (protein 
aminoacids) and from non-protein amino acids such as ornithine. 
However, it is important to note that alkaloids should be derived directly 
from the precursors of aminoacids as, for example, in the case of 
anthranilic acid (the precursor of trypthophan from the shikimate 
                                                          
22 Sheppard, Donald C., et al. "The Aspergillus fumigatus StuA protein governs the up-regulation of a 
discrete transcriptional program during the acquisition of developmental competence." Molecular 
biology of the cell 2005, 16(12): 5866-5879. 
23 Haarmann, Thomas, et al. "The ergot alkaloid gene cluster in Claviceps purpurea: extension of the 
cluster sequence and intra species evolution." Phytochemistry 2005, 66(11): 1312-1320. 
24 Grothe,T.,Lenz,R.andKutchan,T.M. Journal of Biological Chemistry, 2001, 276(33): 30717–30723 
25 Huang, F. C. and Kutchan, T. M. 2000. Phytochemistry, 2000,  53(5): 555–564 
26 Tudzynski, P., Holter, K., Correia, T., Arntz, C., Grammel, N. and Keller, U. Molecular and General 
Genetics, 1999 , 261: 133–141 
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pathway) (Figure 5) or acetate (the precursor of lysine via ketoadipic acid 
and transamination in some algae and fungi). (Figure 6) 
 
Figure 5. Chorismate it’s the final product of Shikimate pathway, as a precursor for   primary 
and secondary metabolites. 
Each biomolecule in living organisms has its own synthesizing, 
transformational and interconverting processes. Therefore, the formation 
of the ring of the alkaloid molecule, and the flow of the nitrogen atom into 
this molecule, is the basic point for understanding alkaloid synthesis and 
its metabolism. 
 
 pag. 25 
 
 
Figure 6. Acetate/Mevanolate and Deoxyxylulose pathway 
Alkaloid biosynthesis needs the substrate. Substrates are derivatives of 
the secondary metabolism building blocks: the acetyl coenzyme A (acetyl-
CoA), shikimic acid, mevalonic acid and 1-deoxyxylulose 5-phosphate. The 
synthesis of alkaloids starts from the acetate, shikimate (Figure 5), 
mevalonate and deoxyxylulose pathways (Figure 6). The acetyl coenzyme 
A pathway (acetate pathway) is the source of some alkaloids and their 
precursors (e.g., piperidine alkaloids or anthranilic acid as aromatized CoA 
ester (antraniloyl-CoA)). Shikimic acid is a product of the glycolytic and 
pentose phosphate pathways, a construction facilitated by parts of 
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phosphoenolpyruvate and erythrose 4-phosphate. The shikimic acid 
pathway is the source of such alkaloids as quinazoline, quinoline and 
acridine. The mevalonate pathway is based on mevalonic acid (three 
molecules of acetyl-CoA) which is closely related to the acetate pathway, 
while the deoxyxylulose phosphate pathway is based on a combination of 
pyruvic acid and glyceraldehyde 3-phosphate (both from the glycolytic 
pathway). Together, mevalonate and deoxyxylulose phosphate pathways 
produce terpenoid and steroid compounds. However, it is important to 
note that the Krebs cycle pathway is also key to many precursors of 
alkaloids. Ornithine, a postcursor of L-arginine in animals and of L-
glutamate in plants, and, for example, L-lysine, a principal protein amino 
acid, deriving from the Krebs cycle pathway compound, are useful 
examples of the role of the Krebs cycle for alkaloid precursors (Figure 7). 
 
Figure 7. Krebs cycle pathway27 
 
                                                          
27  Bruice. P.Y., Essential Organic Chemistry 2nd Ed. 2014 , Pearson.  
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 Moreover, there are other sources of alkaloid substrates, particularly in 
purine alkaloids. Figure 8 represents the general scope of alkaloid 
synthesis in the metabolic system of organisms and their energy 
production. Enzymatic activity is very important in the primary 
metabolism of glycolysis and the Krebs cycle. Pyruvic acid and CoA are key 
compounds in the synthesis of alkaloid precursors. Moreover, these 
precursors (aminoacids) can be derived from different points in the 
glycolysis and Krebs cycles. Consequently, the synthesis of alkaloids as a 
secondary metabolic activity is a very challenging research subject. 
Generally, it is recognized in the literature that alkaloid metabolism in 
animals, and especially in mammals, is closely related to that of plants;  
28,29 however, some exceptions exist. Figure 8 shows two ways of L-
ornithine synthesis. In plants, this non-protein aminoacid is derived from 
L-glutamate and in animals from L-arginine. Moreover, Figure 8 
demonstrates that synthesis of alkaloids is complicated by the ability of 
the same aminoacid to synthesize many different alkaloids. 
 
                                                          
28 Brossi, A. Mammalian alkaloids: Conversion of tetrahydroisoquinoline-1carboxylic acids derived from 
Dopamine. Planta Medica, 1991 57: S93–S100 
29 Xe, X. S., Tadic, D., Brzostowska, M., Brossi, A., Bell, M. and Creveling, C. Helvetica Chimica Acta, 1991 
74: 1399–1411 
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Figure 8. General scheme of alkaloid synthesis. 
 
 Historical Application 1.7
Alkaloidal applications can be found in different areas of the economy, 
industry, trade and services. The applicable characteristics of alkaloids are 
both chemical ones and the ability to be isolated as pure molecules or to 
be modified. The specific activity and utilization is a basis for the 
applications. Alkaloids have been used throughout history in folk medicine 
in different regions around the world. They have been a plants constituent 
part used in phytotherapy. Many of the plants containing alkaloids are just 
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medicinal plants and have been used as herbs. Since the days of 
Hippocrates (460–377 BCE), herbs were known in Europe as a very 
important way of improving health. In ancient China, herbs were known 
and used even since 770 BCE, and in Mesopotamia approximately since 
2000 BCE. In particular in Mesopotamia plants such as Papaver 
somniferum and Atropa belladonna have served to many purpose 
(especially religious), and the use of Datura metel, Cannabis sativa and the 
mushroom Amanita muscaria can be traced to ancient India. Moreover, 
plants containing alkaloids have been historically used for other purposes. 
Hunters, priests, medicine men, witches and magicians have all been 
known to use alkaloidal plants. Humans have used alkaloids as poisons in 
weapons.30 The most poisonous alkaloids such as aconitine and tubocarine 
were used in ancient times as poisons for arrows. Especially in Africa, 
these weapons have been used in tribal warfare, where the poisons 
(alkaloids) were generally prepared from plants but also from animal 
sources as toads, snakes and frogs. 31,32 Poisoned arrows have also been 
used in Asia, especially in the large region including Indonesia, Burma, 
Thailand and Cambodia. Three methods were used in preparing poisons.32, 
33  The first involved boiling arrows in water with a ground up plant. The 
second method used pounded fresh ingredients with glutinous sap added 
(especially in the case of oil-rich plants). The third method involved 
applying freshly squeezed plant material onto wooden-tipped arrows. 
Literature also refers to the fact that different alkaloid groups have been 
used as arrow poisons in different parts of the world. People in Africa and 
                                                          
30 Mann, J. Murder, Magic and Medicine. 1992 London: Oxford University Press 
31 Neuwinger, H. D. African Ethnobotany: Poisons and Drugs, Chemistry, Pharmacology, Toxicology. 
1996, London: Chapman and Hall 
32 Bisset, N. G. Arrow and dart poisons. Journal of Ethnopharmacology, 1989 25: 1–41  
33 Neuwinger, H. D. Alkaloids in arrow poisons. In: Alkaloids. Biochemistry, Ecology, and Medicinal 
Applications (Roberts, M. F. and Wink, M., eds), 1998 pp. 45–84. New York – London: Academic Press. 
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Asia predominantly used cardiac poisons, while South Americans almost 
exclusively preferred muscle-paralyzing (curarizing) poisons.34 Alkaloids 
and especially plants containing alkaloids were also used in the Middle 
Ages as a basic and practical human and animal cure for various ailments. 
Some cases of using alkaloids in executions are also known.34, 35, 36, 37, 38 
Some alkaloids that have played an important role in this sense include 
aconitine, atropine, colchicine, coniine, ephedrine, ergotamine, mescaline, 
morphine, strychnine, psilocin and psilocybin. Although alkaloids have 
been used throughout history, their isolation from plants as relatively pure 
compounds occurred only in the beginning of the 1800s, and their exact 
molecule structures were not determined until the 1900s. 
 Modern Application 1.8
Some alkaloids are still used in medicine today.35, 39, 40, 41, 42 Alkaloids 
generally exert pharmacological activity particularly in mammals such as 
humans. Even today many of our most commonly used drugs are alkaloids 
from natural sources and new alkaloid drugs are still being developed for 
clinical use (e.g., taxol froma Taxus baccata). Most of these compounds 
with biological activity in humans affect the nervous system, particularly 
the action of the chemical trasmitters, e.g. acetylcholine, epinephrine, 
norepinephrine, γ-aminobutyric acid (GABA), dopamine, and serotonin. 
                                                          
34 Bellamy, D. and Pfister, A. Word Medicine. Plants, Patients and People. 1992 Oxford: Blackwell 
35 Schultes, R. A. and Hofmann, A. The Botany and Chemistry of Hallucinegens. 1980 Thomas: Springfield. 
36 Bisset, N. G. Arrow and dart poisons. Journal of Ethnopharmacology, 1989 25: 1–41 
37 Mann, J. Murder, Magic and Medicine. 1992 London: Oxford University Press 
38 Wink, M. Alkaloids. Biochemistry, Ecology, and Medicinal Applications  (Roberts, M. F. and Wink, M., 
eds.), 1998 pp. 11–44. New York – London: Plenum Press. 
39 O’Neil, M. J., Badavari, S., Heckelman, P. E., Merck and Co., Smith, A., D’Arecca, M. A., Gallipeau, J. A. 
R. and Obenchain, J. R. The Merck Index Thirteenth Edition. 2001 New York: John Wiley & Sons 
40 Smeller, T. and Wink, M. Alkaloids. Biochemistry, Ecology, and Medicinal Applications (Roberts, M. F. 
and Wink, M., eds), 1998 pp. 435–459. New York – London: Academic Press 
41 Harborne, J. B. and Baxter, H. Phytochemical Dictionary: A Handbook of Bioactive Compounds from 
Plants. 1993 London: Taylor & Francis 
42 Reynolds, J. E. F. (Ed.. Martindale – The Extra Pharmacopoeia. 1993 London: Pharmaceutical Press 
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Many  alkaloids serve as models for the chemical synthesis of analogues 
with better properties. Important exemples are hyoscyamine and 
scopolamine (Atropa belladonna and Datura species) as models for 
synthetic parasympatholytic agents43; physostigmine (Physostigma 
venenosum) for synthetic parasympathomimetic agents44; tubocurarine 
(Chondodendron tomentosum) for skeletal muscle relaxants; cocaine 
(Erythroxylum coca) for local anesthetic 45; morphine (P. somniferum) for 
analgesics;46 and codeine (P. somniferum) for antitussive agents. These 
molecules have many other pharmacological activities including 
antihypertensive effects (many indole alkaloids)47, antiarrhythmic effects 
(quinidine, ajmaline, sparteine)48, antimalarial activity (quinine)49and 
anticancer effects (dimeric indoles, vincristine, vinblastine)50. These are 
just a few examples illustrating the great economic importance of this 
group of plants constituents. Antibiotic activities are common for alkaloids 
and some are even used as antiseptics in medicine, e.g., berberine in 
ophthalmics and sanguinarine in toothpastes; however, it is difficult to 
know the extent to which alkaloids give antimicrobial protection in the 
plant.51 
                                                          
43 Hofmann, Albert; Schultes, Richard Evans, Plants of the Gods: Origins of Hallucinogenic Use, New York, 
Van der Marck Editions, 1987 pp. 88 
44 Roberto Michele Suozzi, Le piante medicinali Newton&Compton, 1994, pag.35 
45 Francesco Capasso, R. De Pasquale e G. Grandolini, Farmacognosia: Farmaci Naturali, Loro 
Preparazioni Ed Impiego Terapeutico, 2000, Springer Science & Business Media 
46 Beard Jr, Edward L. The American Society of Health System Pharmacists. JONA'S healthcare law, ethics 
and regulation, 2001, 3.3: 78-79. 
47 Horie S, Yano S, Aimi N, Sakai S, Watanabe K. Life Sci. 1992;50(7):491-8 
48 Sneader, Walter, Drug Discovery: A History. 2005.  John Wiley and Sons. p. 95 
49 Dorndorp A, Nosten F, Stepniewska K, et al. Lancet. 2005 366 (9487): 717–25 
50 Takimoto, C. H.; Calvo, E. "Chapter 3: Principles of Oncologic Pharmacotherapy". 2008 In Pazdur, R.; 
Wagman, L. D.; Camphausen, K. A.; Hoskins, W. J. Cancer Management: A Multidisciplinary 
Approach (11th ed.) 
51 Margaret F. Roberts and Michael Wink – Alkaloids: biochemistry, ecology, and medicinal apllications 
1998 Springer Science+Business Media New York 
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Chapter II 
 
2 Marine alkaloids 
 
Marine natural products chemistry is a dynamic field of research which 
had explosive growth in the last decades and is continuing to evolve. 
However, the biological and ecological functions of marine secondary 
metabolites are still poorly understood. Being the result of long 
evolutionary processes of biosynthetic pathway refinement, secondary 
metabolites are considered as products of natural selection and their 
diversity has been tentatively used in chemotaxonomy, complementary 
to morphological characters and/or genetic markers. Therefore, an 
increasing number of integrative taxonomical works on Porifera now 
successfully consider biochemical datasets in parallel to molecular or 
morphological ones.52 
For a long time the man felt that the plants were the only medicinal 
resources at its disposal but the knowledge thirst to other natural 
substances that could improve their quality of life prompted him to look 
elsewhere. His interest, therefore, was addressed to the sea, a truly 
hidden world. Almost with an area twice that land, the sea is home to 
most of the world's flora and fauna. In the deep blue depths of our planet, 
nature seems to have played with shapes and colors to impress every time 
the men. Only since the end of the years ' 60, thanks to the development 
and dissemination of technologies needed for the discovering of the 
                                                          
52 N. Cachet, G. Genta-Jouve, J. Ivanisevic, P. Chevaldonné, F. Sinniger, G. Culioli, T. Pérez, O. P. Thomas, 
Sci. Rep. 2015, 5, 8282 
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marine environment, the chemical study of marine flora and fauna has 
become systematic. A very small part of the organisms that inhabit our 
seas is represented by fish, shells, corals and porifera. In recent years the 
attention of researchers focused mainly on Porifera, commonly known as 
sponges. From these organisms discrete amounts of bioactive metabolites 
were isolated and this was made possible thanks to the development of 
advanced techniques of purification and structural characterization. The 
particular molecular architectures, most unusual and more complex than 
those identified in terrestrial organisms, so as to speak of a separate 
"chemistry of the sea", were thus put in highlights. Some examples of 
secondary metabolites, particularly alkaloids, isolated from sponges, were 
shown (Figures 9-11). 
 
 
 
                 AEROTHIONINE 53 
                   from  Aplysina aerophoba sponge 
(1970) 
        
 
 
 
OROIDINS 54                   
From Agelas oroides sponge     (1971) 
 
 
                                                          
53 E. Fattorusso, L. Minale,G. Sodano, K. Moody,  R.H. Thomson, J. Chem. Soc. Chem.Comm. 1970, 752. 
54 S. Forenza, L. Minale, R. Riccio,  E. Fattoruso, J. Chem. Soc. Chem. Comm. 1971, 1129. 
Figure 9. First marine alkaloid discovered 
Figura 10. First bromoalkaloid discovered 
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    CLATHRIDINE 55, 56 
from Clathrina clathrus sponge (1990) 
 
 
 
However still limited known, the chemical diversity of the sea appears to 
be immense and this is partly due to the fact that, in addition to vegetable 
organisms, in the oceans huge multitude and variety of animal organisms 
live fixed to the seabed or in any case with a very low mobility. The 
coexistence of such a large number of species that interact with each 
other and with the environment, each in a different way, has led to the 
development of life forms capable of accumulating and / or producing a 
wide variety of chemically different compounds with an equally wide 
diversity of possible ecological roles. 
These include: 
A) Toxins, which can reduce predation, the larval settlement and 
overgrowth of neighboring organisms. 
 
B) Compounds capable of reducing the palatability and / or the absorption 
of nutrients in the predators. 
C) Compounds for direct larval settlement and reproduction. 
                                                          
55 P. Ciminiello, E. F attorusso, A. Mangoni, B. DiBlasio, V. Pavone, Tetrahedron Lett. 1990 ,46, 4387 
56 P. Ciminiello, E. Fattorusso, S. Magno, A. Mangoni, Tetrahedron Lett. 1989 45,3873 
Figure 11. First marine alkaloid complexed with zinc 
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Table 2. The odyssey of marine pharmaceuticals a current perspectiv 57 
 
In Table 2 we can see the many marine-derived drugs already approved 
for clinical use and under approval. Focusing our attention to the 
alkaloids, we find, in Phase II, DMXBA, potential drug for the treatment of 
schizophrenia, currently being approved for Phase III and among those 
already approved for clinical use, the trabectedin (Figure 12), alkaloid 
extracted from tunicate Yondelis 58 used for the treatment of ovarian 
cancer. 
 
 
Figure 12. Trabectedin isolated by tunicate Yondelis 
                                                          
57 Alejandro M.S. Mayer et al., TRENDS in Pharmaceuical Sciences 31, 2010, 255-265 
58 D'Incalci, M., CM. Galmarini- Mol Cancer Ther- 2010, 9(8), 2157-63 
Status Compound name Trademark Marine organism Chemical class Disease area 
Approved Cytarabine, Ara-C 
Vidarabine, Ara-A 
Ziconotide 
Trabectedin (ET-743) 
(EU Registered only) 
Cytosar-U® 
Vira- A® 
Prialt® 
Yondelis® 
Sponge 
Sponge 
Conesnail 
Tunicate 
Nucleoside 
Nucleoside 
Peptide 
Alkaloid 
Cancer 
Antiviral 
Pain 
Cancer 
Phase III EribulinMesylate(E7389) 
Soblidotin (TZT 1027) 
NA 
NA 
Sponge 
Bacterium 
Macrolide 
Peptide 
Cancer 
Cancer 
Phase II DMXBA (GTS-21) 
 
Plinabulin (NPI-2358) 
Plitidepsin 
Elisidepsin 
PM1004 
Tasidotin (ILX-651) 
Pseudopterosins 
NA 
 
NA 
Aplidin® 
Irvalec® 
Zalypsis® 
NA 
NA 
Worm 
 
Fungus 
Tunicate 
Mollusc 
Nudibranch 
Bacterium 
Soft coral 
Alkaloid 
 
Diketopiperazine 
Depsipeptide 
Depsipeptide 
Alkaloid 
Peptide 
Diterpene glycoside 
Cognition 
Schizophrenia 
Cancer 
Cancer 
Cancer 
Cancer 
Cancer 
Wound healing 
Phase I Bryostatin 1 
Hemiasterlin (E7974) 
Marizomib(Salinosporamide A; 
NPI-0052) 
NA 
NA 
NA 
Bryozoa 
Sponge 
Bacterium 
Polyketide 
Tripeptide 
Beta-lactone-gamma lactam 
Cancer 
Cancer 
Cancer 
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 Marine guanidine alkaloids 2.1
The sponges are characterized by the presence inside of bioactive 
secondary metabolites pharmacologicaly interesting from different points 
of view, both structural and biosynthetic. Among these, the sponges 
belonging to the family Microcionidae and being part of the order 
Poecilosclerida, are particularly known as they contain polycyclic guanidine 
alkaloids used in therapy.59,60,61 Three main families of this type of alkaloids 
is representative of the pentacyclic alkaloids Poecilosclerida order: 
crambescidine ureas as, those antidepressants such as batzelladine, and 
those compounds such as mono-and/or crambine. 
 Guanidine pentacyclic alkaloids 2.2
The first metabolite of this family, isolated in 1989 from the Caribbean 
sponge Batzella sp. (identified as Ptilocaulis spiculifer) is the Ptilomycalina 
A 62 (Figure 13). 
 
 
This compound is characterized by cytotoxic and antiviral activities. 
                                                          
59 R.G.S. Berlinck, M.H. Kossuga, Nat. Prod. Rep., 2005, 22, 526-550 
60 R.G.S. Berlinck, Nat. Prod. Rep., 2002, 19, 617-649 
61 R.G.S. Berlinck, Nat. Prod. Rep., 1999, 16, 339-365 
62 Y. Kashman, S. Hirsh, O.J. McConnell, T. Ohtani, H. Kusumi, H. Kakisawa, J. Am. Chem. Soc., 1989, 111, 
8925-8926. 
Figure 13. Ptilomycalina A isolated by caribbean sponge Batzella sp. 
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In 1991, Jares-Erijman et al.63 first isolated the Crambescidine (6-9 in 
Figure 14) from a sponge (Crambe crambe)  in the Mediterranean. 
 
 
Figura 14. Crambescidine isolated from sponge Crambe crambe 
 
Since then, different guanidine alkaloids have been isolated from sponges, 
the vast majority of which has pharmacological activity as antimicrobial, 
antiviral, antifungal, antiparasitic and/or chemotherapy. 
 
 Guanidine tricyclic alkaloids 2.3
There are two major subfamilies of this type of alkaloids which differ by 
the location of the tricyclic guanidine pattern. 
I) The first subfamily consists of alkaloids that have the tricyclic guanidine 
moiety in the out position overall.  
The ptilocaulina (10) and the isoptilocaulina (11), in Figure 15, isolated in 
1981 by Ptilaucaulis spiculifer are the first representatives of this 
                                                          
63 E.A. Jares-Erijman, R. Sakai, K.L. Rinehart, J. Org. Chem., 1991, 56, 5712-5715. 
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subfamily.64 
To date, the final metabolite entered this subfamily is mirabilina G (12 in 
Figure 15), isolated in 2001 from the australian sponge Clathria.65 
 
 
 
Figura 15. Ptilocauline (10) Isoptilocauline (11) Mirabiline G (12) 
 
II) The second subfamily is composed of alkaloids which have the central 
tricyclic guanidine pattern.  
 The first belonging to this second subfamily are the Batzelladine A, D and 
F (Figure 16) discovered for the first time in 1995 by Batzella sponge in the 
Bahamas.66 
 
                                                          
64 G.C. Harbour, A.A. Tymiak, K.L. Rinehart, P.D. Shaw R.  Hughes, S.A. Mizsak, J.H. Coats, G.E. Zurenko 
L.H. Li, S.L. Kuentzel, J. Am. Chem. Soc., 1981, 103, 5604-5606. 
65 Capon, R.J. ; Miller, M. ; Rooney, F. J. Nat. Prod., 2001, 64, 643-644. 
66 Patil, A.D. ; Kumar, N.V. ; Kokke, W.C. ; Bean, M.F. ; Freyer, A.J. ; Brosse, C.D. ; Mai, S. ; Truneh, A. ; 
Carte, B. J. Org. Chem.,1995, 60, 1182-1188. 
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Figure 16. Batzelladine A (13) Batzelladine B (14) Batzelladine F (15) 
 
Compared to ptilocaulina (10 in Figure 14), batzelladine (13-15 in Figure 
16) are characterized not only by the central location of the Guanidine in 
tricycle but batzelladine A (13) and F (15) have in addition a bicyclic or 
tricyclic Guanidine pattern tied with an alkyl chain on the first tricycle. The 
batzelladine have been tested as anti-HIV agents: a cheering activity was 
detected for batzelladina A (13), while moderate to batzelladina F (15) and 
no activity for batzelladina D (14); from this, the presence of the bicycle is 
indispensable for anti-HIV activity. The last metabolites related to this 
second subfamily have been recently isolated from a sponge of the genus 
Monanchora; the merobatzelladine A and B (16-17 – Figure 17) that 
exhibit antibacterial activity.67 
                                                          
67 Takishima, S. ; Ishiyama, A. ; Iwatsuki, M. ; Otoguro, K. ; Yamada, H. ; Omura, S. ; Kobayashi, H. ; Van 
Soest, R.W.M. ;Matsunaga, S. Org. Lett., 2009, 11, 2655-2658 
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Figure 17. Merobatzelladine A and B isolated by sponge Monanchora 
 
 Guanidine mono- and bi-cyclic alkaloids 2.4
The first representatives of the family of mono- and bi-cyclic guanidine 
alkaloids are the Crambine A and B (18-19 in Figure 18), isolated from 
Mediterranean sponge crambe crambe in 1990.68 
 
 
Figure 18. Crambine A and B isolated by sponge Crambe Crambe 
 
Jares-Erijman et al. and then Snider et al. later overhauled the structure of 
Crambine B (19) which has been renamed Crambescina B, and have also 
defined the stereochemistry as well as shown in Figure 18.69,70 The 
                                                          
68 Berlinck, R. G. S. ; Braekman, J. C. ; Daloze, D. ; Hallenga, K. ; Ottinger, R. ; Bruno, I. ; Riccio, R. 
TetrahedronLett., 1990, 31,6531-6534 
69 Jares-Erijman, E. A. ; Ingrum, A. A. ; Sun, F. ; Rinehart, K. L. J. Nat. Prod., 1993, 56, 2186-2188 
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crambine have no interesting biological activity.71  After the study on the 
Crambine A (18) and on the difference of activity compared with the 
batzelladine A (13), with an extra bicycle, and the batzelladine D (14), it 
was concluded that the task is not only due to the presence of the bicycle 
but also to the synergy of two bi-and tri-cyclic reasons. 
 
 
 
 
  
                                                                                                                                                                          
70 Snider, B. B. ; Shi, Z  J. Org. Chem., 1992, 57, 2526-2528 
71 Patil, A.D. ; Kumar, N.V. ; Kokke, W.C. ; Bean, M.F. ; Freyer, A.J. ; Brosse, C.D. ; Mai, S. ; Truneh, A. ; 
Carte, B. J. Org. Chem.,1995, 60, 1182-1188 
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Chapter III 
 
3 Parazoanthus axinellae 
 
Although sponges are the paramount source of marine bioactive 
metabolites, cnidarians, and especially anthozoans, display high 
biological and chemical diversity and as such they have been the focus 
of many promising researches on natural products.72,73 
 
 
Figure 19. Sea Daisy Parazoanthus axinellae  – photo L. Capurro. 
                                                          
72 Behenna, D. C., Stockdill, J. L. & Stoltz, B. M. The Biology and Chemistry of the Zoanthamine 
Alkaloids. Angew. Chem., Int. Ed. 2008, 47, 2365–2386. 
73 Rocha, J., Peixe, L., Gomes, N. C. M. & Calado, R. Cnidarians as a Source of New Marine Bioactive 
Compounds—An Overview of the Last Decade and Future Steps for Bioprospecting. Mar. Drugs 9, 
2011, 1860–1886. 
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Among them, relatively little is known about zoanthids (Cnidaria, 
Hexacorallia, Zoantharia) despite the fact that they are common in most 
shallow and deep marine environments. The phylum Cnidaria, containing 
more than 9,000 species, get a particularly interesting example. 
 
Figure 20. Cnidaria animals 
 
Figure 21. Cnidaria family 
In particular, in the class of the Anthozoans, subclass Hexacorallia, there is 
a species of sea anemone, Parazoanthus axinellae (Figure 19), widespread 
in the Mediterranean and Eastern Atlantic Ocean; it is often associated 
with sponges of the genus Axinella or sea squirts like Microcosmus. 
Parazoanthus axinellae is a common organism in sublittoral rocky 
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communities, especially in habitats with low light irradiance, on shaded 
vertical cliffs, overhangs and at cave entrances. A new family of 
guanidine alkaloids was found from this anemone: parazoanthine A-J 
(Figure 22).74,75 
 
Figure 22. Parazoanthine A-J isolated from Parazoanthus axinellae sea anemone 
 
The secondary metabolome of P. axinellae was first studied in the 
1970s with the isolation and structure elucidation of polyaromatic 
alkaloids named zoanthoxanthins and parazoanthoxanthins76,77,78 
Recently, a second original family of alkaloids, named parazoanthines, 
                                                          
74 Nadja Cachet, Gregory Genta-Jouve, Erik L. Regalado, RedouaneMokrini, Philippe Amade, Gerald 
Culioli, and Olivier P. Thomas. J.Nat.Prod. 2009, 72, 1612-1615. 
75 Audoin, C. et al. Metabolome Consistency: Additional Parazoanthines from the Mediterranean 
Zoanthid Parazoanthus Axinellae. Metabolites 4, 421–432 (2014) 
76 Cariello, L., Crescenzi, S., Prota, G., Giordano, F. & Mazzarella, L. J. Chem. Soc., Chem. Commun., 
1973, 99–100. 
77 Cariello, L. et al.  Tetrahedron, 1974, 30, 3281–3287. 
78 Cariello, L., Crescenzi, S., Prota, G. & Zanetti, L.  Experientia, 1974, 30, 849–850. 
 pag. 45 
 
was recovered from the same species.79 This new family of compounds 
was found to be very interesting as a biosynthetic standpoint and is the 
first example of natural products in which the hydantoinic core is 
disubstituted in N-3 and C-5; in fact the hydantoins known natural 
nowadays are not replaced in N-3 and in rare cases there is only one 
methyl substitution. 72 
From the point of biosynthetic view the hydantoins are considered the 
connection key for the formation of peptides derived from purine.80 
The key reaction, in the first hypothesis proposed for the biosynthetic 
scheme (Figure 23), is the mono carbonylation taking place after the 
condensation of two aminoacids; in the second proposed hypothesis we 
have the contraction of a diketopiperazinic ring obtained from double 
condensing of two amminoacids. 
 
Figura 23. Biosynthetic scheme of hydantoinic ring 
                                                          
79 Cachet, N. et al.  J. Nat. Prod. 2009, 72, 1612–1615. 
80 Huber, C. ; Eisenreich, W. ; Hecht, S. ; Waechtershaeuser, G. Science, 2003, 301, 938–940. 
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 In silico screening of parazoanthines as potential CXCR4 3.1
ligands  
In a previous work81, a minimalist pharmacophoric model was developed 
for CXCR4 ligands that led to the identification of phidianidine A (Figure 
24) , an alkaloid compound from marine source, as CXCR4 inhibitor 
endowed with low micromolar activity.  
N
HBr
N
NO
NH
N
H
HN
NH25
 
Figure 24. Phidianidine A 
In this pharmacophoric model, the essential anchoring points for this 
receptor consist in a single pair of properly spaced aromatic and 
guanidinic functional groups, with the an upper limit of 18 Å for the 
distance between the two centers of mass. The search for new naturally-
occurring molecules featuring the aforementioned requisites in our ICB 
collection gave parazoanthines (PARA) compounds, hydanthoin alkaloids 
from Mediterranean Sea Anemone Parazoanthus axinellae, as potential 
new CXCR4 ligands. The compounds within this family, named A-C, differ 
each other for the presence of an hydroxyl (A-B) or methoxy (C) group on 
the phenyl ring, and for the number of double bonds in the structure: two 
(Δ5,6 and Δ13,14) for B-C and only one (Δ13,14) for A. While sharing a 
                                                          
81 Vitale RM, Gatti M, Carbone M, Barbieri F, Felicità V, Gavagnin M, Florio T, Amodeo P. Minimalist 
hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine 
natural products led to the identification of phidianidine a as a new CXCR4 ligand exhibiting antagonist 
activity. ACS Chem Biol. 2013 Dec 20;8(12):2762-70. 
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common guanidinium group, they differ from phidianidine in both the 
aromatic portion (phenyl vs indole ring) and in the length and nature of 
spacer, since they bring an hydanthoin group in place of an oxadiazole ring 
and double in place of single bond(s) in the carbon chain, as well as in the 
distance between the two anchoring groups (~14Å), smaller than that 
found in phidianidine. Since, in spite of the agreement with the (rather 
loose) pharmacophoric model, these substantial differences make the 
activity of the new compounds on CXCR4 not completely anticipatable, 
they underwent a cycle of computational and experimental validation. 
Docking calculations (done by Dr. Piero Amodeo and Dr. Rosamaria Vitale 
of ICB) of PARA A-C into CXCR4 structure (PDB entry 3OE0) give as best 
poses for each compound a similar arrangement in the binding site: all 
compounds form bidentate H-bonds reinforced by ionic interactions with 
Asp97 and Asp187, H-bonds with the hydanthoin group and Asp187 and 
the NH backbone atom of Arg188, whereas the aromatic ring is 
sandwiched between Arg188 and Tyr116, with the hydroxyl group 
engaging an H-bond with Thr117. This last H-bond does not occur in PARA-
C, due to the presence of the methoxy group, since Thr117 acts as H-bond 
acceptor in PARA-A and PARA-B ligands, being its polar hydrogen in turn 
involved in H-bond with backbone CO of His113. To best explore the 
potential role of both such H-bond, and the nature of the aromatic group, 
two non natural derivatives were also considered: one bearing a phenyl 
group the 18-deoxy-parazoanthine (5) and another bearing a naphthalene 
group (PARA-N). All energy minimized complexes are reported in Figure 
25A-D.  
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Figure 25A. Parazoanthine A 
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Figure 25B. Parazoanthine B 
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Figure 25C. Parazoanthine C 
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Figure 25D. Parazoanthine N 
 
Figures 25A-D. CXCR4 complexes with PARA-A, -B, -C, -N ligands are shown adopting a 
partially-transparent tan ribbon representation for protein backbone, sticks for protein side 
chains within 5 Å from the ligand and ball and sticks for ligand. Only polar hydrogen atoms are 
shown. Atoms are colored according to the following scheme: O=red, N=blue, H=white, 
S=yellow. PARA-A, -B, -C, -N carbon atoms are colored in steel blue, sky blue, green and plum, 
respectively. Ligand-protein H-bonds are depicted with a green spring. All figures are plotted 
with Chimera program. 
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 CXCR4 receptor 3.2
CXC chemokine ligand (CXCL)12 (also known as stromal cell-derived factor 
[SDF]-1 or pre-B-cell-growth-stimulating factor [PBSF]) is a member of a 
large family of structurally related chemoattractive cytokines and was first 
characterized as a growth-stimulating factor for the B cell precursor 
clone.82 The primary physiologic receptor for CXCL12 is CXCR4, a hepta 
helical receptor coupled to heterotrimeric guanosine triphosphate (GTP) 
binding proteins, which also functions as an entry receptor for the HIV-1 
virus. 83,84,85 
Studies of mutant mice with targeted gene disruption have revealed that 
CXCL12-CXCR4 signaling is essential for hematopoiesis, including B cell 
development and colonization of bone marrow by hematopoietic 
progenitors, including HSCs (Hematopoietic stem cells), during ontogeny 
as well as cardiovascular formation and neurogenesis. 82,83,84,86,87 
 
Lethality caused by deficiencies of CXCL12 and CXCR4 prevents immediate 
analysis of their role in adult hematopoiesis. Treatment with CXCR4-
selective antagonist induces increase in HSCs in the peripheral blood, 
suggesting a role for CXCL12 in retaining HSCs in hematopoietic organs.88 
                                                          
82 T. Nagasawa, H. Kikutani, T. Kishimoto Proc. Natl. Acad. Sci. USA, 91, 1994, pp. 2305–2309 
83 T. Nagasawa, S. Hirota, K. Tachibana, N. Takakura, S. Nishikawa, Y. Kitamura, N. Yoshida, H. Kikutani, T. 
Kishimoto Nature, 1996, 382, pp. 635–638 
84 K. Tachibana, S. Hirota, H. Iizasa, H. Yoshida, K. Kawabata, Y. Kataoka, Y. Kitamura, K. Matsushima, N. 
Yoshida, S. Nishikawa, et al. Nature, 1998, 393, pp. 591–594 
85 Y.R. Zou, A.H. Kottmann, M. Kuroda, I. Taniuchi, D.R. Littman, Nature, 1998, 393, pp. 595–599 
86 T. Ara, K. Tokoyoda, T. Sugiyama, T. Egawa, K. Kawabata, T. Nagasawa Immunity, 2003, 19, pp. 257–
267 
87 T. Nagasawa Nat. Rev. Immunol., 2006, 6, pp. 107–116 
88 H.E. Broxmeyer, C.M. Orschell, D.W. Clapp, G. Hangoc, S. Cooper, P.A. Plett, W.C. Liles, X. Li, B. 
Graham-Evans, T.B. Campbell, et al. J. Exp. Med., 2005, 201, pp. 1307–1318 
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CXCL12-CXCR4 signaling is essential in adult bone marrow to maintain the 
HSC pool and suggest that many HSCs are in contact with a small 
population of reticular cells expressing high amounts of CXCL12.89 
In addition, almost all HSCs near the sinusoidal endothelium appear to be 
in contact with these reticular cells surrounding endothelial cells in the 
extravascular spaces, suggesting that these cells are the key cellular 
components of HSC vascular niches.90 
 
 
 
Figure 26. CXCR4 antagonists in human immunodeficiency (HIV-1) and cancer. 
 
CXCR4 is the co-receptor used along with CD4 by T cell-tropic (X4) HIV-1 
strains for cellular entry into T cells. A trimeric unit of viral envelope 
glycoproteins (gp120) that are anchored by gp41 binds CD4 on the surface 
                                                          
89 K. Tokoyoda, T. Egawa, T. Sugiyama, B.I. Choi, T. Nagasawa Immunity, 2004, 20, pp. 707–718 
90 T Sugiyama, H Kohara, M Noda, T Nagasawa - Immunity, 2006, 25, pages 977-988 
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of T cells, inducing a conformational change of gp120, allowing it to 
interact with CXCR4 through the V3 loop of gp120. CXCR4 antagonists 
block the CXCR4-binding site for X4 HIV-1, and thereby prevent fusion of 
HIV-1 with T cells.  
Stromal fibroblasts within the tumor microenvironment secrete CXCL12 
and thereby attract and retain tumor cells in contact with the stroma. 
Adhesion of tumor cells to stromal cells confers survival, growth and drug 
resistance signals (cell adhesion-mediated drug resistance (CAM-DR)) that 
are, at least in part, mediated by activation of CXCR4 on the tumor cells. 
Stromal cell-mediated activation of CXCR4 is also called a 'paracrine' 
activation of tumor cells through CXCL12.91 CXCR4 antagonists can disrupt 
the adhesive interactions between tumor cells and tumoral fibroblasts, 
mobilizing them from the tumor microenvironment, and making the 
tumor cells more accessible to cytotoxic drugs.  
Tumor cells (hematopoietic and non-hematopoietic) also utilize the 
CXCR4-CXCL12 axis to migrate and home to target organs, such as the 
marrow. CXCL12 is constitutively secreted by marrow stromal cells retains 
leukemia cells in protective marrow niches and attracts circulating tumor 
cells for directional homing/metastasis. CXCR4 antagonists can inhibit this 
mechanism of tumor cell homing by blocking CXCR4 receptors responsible 
for migration to CXCL12-secreting stromal cells, thereby mobilizing tumor 
cells from tissue sites, such as the marrow.92   
 
                                                          
91  Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R et al. Cell 2005; 121: 335–
348. 
92 J A Burger, A Peled  Leukemia, 2009, 23, 43–52 
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In summary, the rationale for targeting CXCR4 with CXCR4 antagonists in 
leukemia and other cancers is as follows: 
1. disrupting the adhesive stromal interactions that confer survival and 
drug resistance signals to leukemia and other cancer cells; 
2. mobilizing tumor cells from tissue sites, such as the marrow, and 
thereby making them better accessible to conventional therapy; 
3. blocking of migration and dissemination of tumor cells in the 
process of tumor cell metastasis; 
4. blocking of paracrine growth and survival signals through activation 
of the CXCR4-CXCL12 axis and 
5. blocking pro-angiogenesis effects of CXCL12. 
 CXCR4 antagonists 3.3
CXCR4 antagonists were initially developed as new drugs for the 
treatment of HIV-1 infection. At the time of their discovery in the early 
1990s, the mechanism of anti-HIV activity of the most prominent CXCR4 
antagonists, T140 and its analogs,93, 94 AMD3100 95, 96 and ALX-4C,65 was 
unknown. After the discovery of the co-receptor function of CXCR4 for T 
tropic HIV-1, the specific CXCR4-blocking function of the different CXCR4 
antagonists was rapidly demonstrated.97, 98 
                                                          
93 Nakashima H, Masuda M, Murakami T, Koyanagi Y, Matsumoto A, Fujii N et al. Antimicrob Agents 
Chemother 1992; 36: 1249–1255. 
94 Masuda M, Nakashima H, Ueda T, Naba H, Ikoma R, Otaka A et al. Biochem Biophys Res Commun 
1992; 189: 845–850. 
95 De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K et al Antimicrob Agents 
Chemother 1994; 38: 668–674 
96 De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H et al. Proc Natl Acad Sci USA 
1992; 89: 5286–5290 
97 Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES et al.. J Exp Med 1997; 186: 
1395–1400 
98  Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H et al. A small molecule CXCR4 
inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997; 186: 1389–1393. 
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Cancer type In vitro studies In vivo studies 
Solid tumors 
 Breast cancer AMD3100: blocks CXCL12-induced HER2-neu activation 
T140: reduced metastasis 
in murine model; 
AMD3100: prolongs 
survival in murine model 
 Small cell lung cancer 
(SCLC) 
T140 and its analogs block 
adhesion and survival pathways   
 Pancreatic cancer AMD3100 inhibits tumor cell migration and growth   
 Cholangiocarcinoma AMD3100 inhibits tumor cell migration   
 Gastric cancer   AMD3100 reduced tumor growth in a murine model 
 Colorectal cancer AMD3100 inhibits tumor cell growth   
 Malignant melanoma AMD3100 inhibits tumor cell activation and proliferation 
T140 analog inhibits 
metastatic melanoma, T22 
increases efficacy of 
immunotherapy in 
metastatic melanoma 
 Glioma AMD3100 inhibits tumor cell invasion   
 Other CNS tumors   
AMD3100 inhibits 
glioblastoma and 
medulloblastoma growth 
in xenograft model 
 Ovarian cancer AMD3100 inhibits cancer cell migration and activation   
 Rhabdomyosarcoma T140 blocked in vitro responses to CXCL12    
 Prostate cancer T140 blocks tumor cell invasion and signaling   
      
Leukemia/lymphoma 
 Chronic lymphocytic 
leukemia (CLL) 
T140, TC14012 and TN14003 
block migration, adhesion and 
stromal protection; AMD3100 
blocks actin polymerization in 
CLL cells 
  
 Acute myelogenous 
leukemia (AML) 
RCP168 and AMD3465 block 
migration and CXCR4 
signaling; AMD3100 reduced 
  
 pag. 57 
 
Cancer type In vitro studies In vivo studies 
AML cell survival 
 Acute lymphoblastic 
leukemia (ALL) 
T140 and its analogs and 
AMD3100 inhibit ALL cell 
migration and adhesion 
T140 analogs, AMD3100 
and AMD3465 mobilize ALL 
cells 
 Multiple myeloma T140 analogs block CXCL12-induced osteoclast activity 
AMD3100 inhibits in 
vivo homing of myeloma 
cells 
 Non-Hodgkin's 
lymphoma   
CXCR4 neutralization 
inhibited lymphoma 
growth 
Table 3. In vitro and in vivo efficacy of CXCR4 antagonists in solid tumors and 
leukemia/lymphoma 99 
 
 
 
Figure 27. Effects on cell migration and podia formation.The effect of the SDF-1a, CXCR4 
agonist, and CXCR4 antagonists on migration of human CD34+ cells was assessed in transwell 
migration experiments.100 
                                                          
99 J A Burger, A Peled  Leukemia, 2009, 43–52 
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In general, four major classes of CXCR4 antagonists and agonists can be 
distinguished:  
(a) small peptide CXCR4 antagonists, such as T140 and its analogs 
(TN14003 and others). However the precise mechanism of anti-HIV 
activity remained unclear until the discovery that T tropic HIV-1 (X4-HIV-1) 
utilizes CXCR4 as a co-receptor for cellular entry into CD4-positive T cells. 
Soon after this, it was demonstrated the T22 speciﬁcally binds to CXCR4 
and blocks CXCR4 receptor regions that are critical for HIV-1 viral entry 
and for activation by its natural ligand, CXCL12. The efﬁcacy of T140 and 
its analogs for blocking CXCR4 in vitro and in vivo has been documented in 
numerous preclinical studies, including in vivo models for breast cancer 
and melanoma,101, 102 rheumatoid arthritis 103 and stem cell mobilization.104 
Other studies explored the activity of these agents in acute105, 106 and 
chronic leukemias,107 multiple myeloma,108 small cell lung cancer (SCLC),109 
malignant melanoma92 and pancreatic cancer.110 
(b) non-peptide CXCR4 antagonists, such as the bicyclam AMD3100. This 
is a speciﬁc antagonist of CXCL12 binding to CXCR4, inhibiting 
                                                                                                                                                                          
100 A. Faber, C. Roderburg, F. Wein, R. Saffrich,  A. Seckinger,  K. Horsch,  A. Diehlmann, D. Wong, G. 
Bridger,  V. Eckstein,  A. D. Ho, W. Wagner Journal of Biomedicine and Biotechnology 2007. 
101 Takenaga M, Tamamura H, Hiramatsu K, Nakamura N, Yamaguchi Y, Kitagawa A et al. Biochem 
Biophys Res Commun 2004; 320: 226–232 
102 Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H et al. FEBS Lett 2003; 550: 
79–83. 
103 Tamamura H, Fujisawa M, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N et al. FEBS Lett 
2004; 569: 99–104. 
104 Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E et al. Stem Cells 2007; 25: 2158–2166. 
105 Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Leukemia 2003; 17: 1294–1300. 
106 Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A et al. Leukemia 2007; 21: 1249–1257. 
107 Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N et al. Blood 2005; 106: 1824–1830. 
108 Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK et al. Cancer Res 2005; 65: 
1700–1709. 
109 Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N et al. Oncogene 2003; 22: 
8093–8101. 
110 Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K et al. Mol Cancer Ther 2004; 3: 29–37. 
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CXCL12mediated calcium mobilization, chemotaxis and GTP binding, and 
does not cross-react with other chemokine receptors. 111   
(c) antibodies to CXCR4. Neutralizing the interaction between CXCL12, the 
ligand for CXCR4, and CXCR4 by using anti-CXCR4 antibodies signiﬁcantly 
inhibit HIV infection and tumor cell migration in vitro. Furthermore, anti-
human CXCR4 or CXCL12 antibodies also signiﬁcantly impair metastasis 
and progression of non-Hodgkin’s lymphoma, breast, lung and prostate 
tumors in animal models.112, 113 
(d) modiﬁed agonists and antagonists for SDF-1 such as CTCE-9908 and 
CTCE-0214 are peptide analogs of CXCL12 with inhibitory and agonist 
activity, respectively. CTCE-9908 that has received orphan drug status by 
the Food and Drug Administration for the treatment of osteogenic 
sarcoma. CTCE-9908 decreases growth and adhesion of osteosarcoma 
cells and the metastatic dissemination of cancer cells in two murine 
models.114 
Product 
name Company Structure Administration Indication 
Study 
phase 
Plerixafor 
(AMD3100) Genzyme Bicyclam s.c. 
Stem cell 
mobilizatio
n 
Phase III 
AMD070 Genzyme Bicyclam derived Oral HIV Phase I/II 
CTCE-9908 
antagonist 
Chemokine 
Therapeutics 
Corp. 
Modified 
SDF-1 s.c./i.v. 
Solid 
tumors Phase I/II 
CTCE-0214- Chemokine Modified s.c./i.v. Mobilizatio Phase I/II 
                                                          
111 Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR et al. Biochem Pharmacol 2006; 72: 
588–596. 
112 Bertolini F, Dell’Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S et al. Cancer Res 2002; 62: 
3106–3112. 
113 Engl T, Relja B, Marian D, Blumenberg C, Muller I, Beecken WD et al. Neoplasia 2006; 8: 290–301. 
114 Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH et al. Clin Exp Metastasis 2008; 25: 201–
211. 
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Product 
name Company Structure Administration Indication 
Study 
phase 
agonist Therapeutics 
Corp. 
SDF-1 n BM 
recovery 
No name 
Northwest 
Biotherapeutic
s, Bethesda, 
MD, USA 
Antibody s.c./i.v. Cancer Preclinical 
TG-0054 
TaiGen 
Biotechnology 
Co., Taipei, 
Taiwan 
? ? 
Stem 
mobilizatio
n for 
regenerati
on 
Phase I/II 
BKT140 Biokine Therapeutics 
Modified 
peptide s.c./oral 
MM and 
leukemia Phase I 
Table 4. CXCR4 antagonists that are currently in preclinical and clinical development.115 
  
                                                          
115 J A Burger, A Peled  Leukemia, 2009; 23, 43–52 
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Chapter IV 
 
4 Parazoanthines synthesis 
 
The chemical preparation of natural metabolites and their analogs is of 
paramount importance for the biological and pharmacological studies of 
natural bioactive molecules. 
Generally for the success of this kind of project is necessary to choose 
appropriately reactants and reaction conditions. The purpose of each 
synthesis is getting production of the desired product with the highest 
yields and purity possible, through a sequence of chemical reactions, 
which provides for the formation of a series of intermediates. The 
identification of synthetic strategy involves a preliminary phase of 
research in literature to identify any previously used methods for the 
production of intermediates of interest for synthesis. During the synthetic 
strategy the intermediates are compounds, to obtain which, methods are 
developed by following general rules, and theswe methods are called 
methodologies. Such methods should possibly give high yields and be 
available for a large number of substrates. Methodology research usually 
takes place in three stages: discovery, optimization, and studio 
applications and limitations. The discovery may provide a targeted 
method, when you search for substances in plant or animal compounds, 
through extractive methods and characterization at the highest 
technological level; or alternatively we rely on randomness of discovery 
(Serendipity), starting from the observation of an unexpected, unusual or 
unexpected data that has allowed to discover molecules with high 
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pharmacological activity (eg. Fleming with penicillin). Optimization 
involves a study aimed at improving the reaction conditions, as the 
variation in temperature, the duration of the reaction, the suitable 
selection of the solvent, the relative amounts of reagents, until optimum 
conditions indeed enhance the achievement of the desired molecule in 
maximum yield and purity. The third stage instead provides this program 
to a wide class of substrates, to verify its applicability. 
During my PhD at the Institute of Biomolecular Chemistry, CNR, Pozzuoli 
(NA), Italy, I was involved in continuing the project started during the 
period of my thesis. 
My project was focused on the chemical synthesis of most representative 
natural parazoanthines and no natural analogs leading to the preparation 
of discrete amount of these compounds to test in pharmacological assays 
to develop their pharmaceutical potential eventually confirming the in 
silico screening of parazoanthines compounds as potential CXCR4 ligands. 
The synthesis of alkaloids and particularly of parazoanthines was 
immediately very interesting because they have unique structural 
chemical characteristics. The hydantoinic disubstituted ring gives flatness 
and rigidity to the molecule, that presents a guanidine linker bound to the 
ring at C-5 with a double or single bond depending on the parazonathine. 
The presence of the double bond (parazoanthine B eg) led to design 
synthetic strategy different from that developed for derivatives without 
the double bond (parazoanthine A eg.). 
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  Parazoanthine-A and its O-Me derivative synthesis116 4.1
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2 : R = OCH3
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13
14
6
 
 
Figure 28. Parazoanthine A (1) and O-Me (2) 
 
Inspired by nature the knowledge and the hypothesis of biosynthetic 
mechanisms, by which these molecules are naturally produced, could help 
us to design a strategy of chemical synthesis. 
In fact parazoanthine A and its O-methyl derivative (Figure 28) were 
prepared by a concise biomimetic synthesis based on the coupling 
reaction of L-arginine methyl ester dihydrochloride with isocyanate 
derivatives of p-coumaric acid and 4-methoxy-cinnamic acid, respectively. 
The synthetic approach is designed to obtain a wider class of 
parazoanthine analogs, with single bond on C5-C6.  
To this aim, we found a literature method for the synthesis of hydantoin 
cores based on hypothesized biosynthetic mechanisms (Figure 23).  
In Stilz et al. procedure117  the coupling between L-arginine O-methyl ester 
with isocyanate derivative by use of N-ethylmorpholine in N,N-
                                                          
116 Manzo, E.; Pagano, D.; Nuzzo, G.; Gavagnin, M.; Ciavatta, M.L. Tetrahedron Lett. 2012, 53(52), 7083-
7084 
117 Stilz, H.U.; Guba, W.; Jablonka, B.; Just, M.; Klingler, O.; Konig, W.; Wehner, V.; Zoller, G. J. Med. 
Chem. 2001, 44, 1158-1176 
 
 pag. 64 
 
dimethylformamide (DMF) led to the formation of the hydantoin 
framework by the subsequent treatment with 6 N HCl under reflux (Figure 
29). 
 
H2N NH
NH
H
NH2
CO2CH3 H2N NH
NH
H CO2CH3
HN
O
H
N CO2Et
H2N NH
NH
H
HN
O
N
O
CO2H
N-ethylmorpholine
HCl, RefluxCO N CO2Et
+
DMF
*
 
 
Figure 29. Stilz et al methodology 117 to obtain hydantoinic ring 
 
According to this procedure, we planed the synthetic strategy in which the 
key-step was the coupling (Figure 30) between the commercially available 
L-arginine methyl ester dihydrochloride and the opportunely prepared 
isocyanates A or A’, by using N-ethylmorpholine in DMF. We observed 
that in our case, differently from literature data, the formation of the 
hydantoin moiety just occurred after the treatment with N-
ethylmorpholine in DMF whereas the following use of 6 N HCl revealed to 
be disadvantageous because of the formation of a complex mixture of 
products. Thus, this step was not considered in our synthetic scheme. 
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Figure 30.  Coupling reaction to obtain the parazoanthine A (1) and its O-methyl derivative (2) 
 
In Figure 31 the mechanism, relating to the coupling between the 
isocyanate (A or A’) and the L-arginine methyl ester dihydrochloride, is 
represented to obtain respectively the parazoanthina A (1) or its O-Me 
derivative (2).  
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Figure 31. Coupling mechanism to obtain Parazoanthine A or its OMe-derivative. 
 
 
The amino group of L-arginine methyl ester attacks the electrophilic 
carbon of the isocyanate by an addition mechanism to form a N-
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substituted guanidine derivative; subsequently the amide nitrogen attacks 
the carboxylic carbon of the methyl ester by a nucleophilic acyl 
substitution mechanism eliminating methanol and thus leading to the 
hydantoinic ring formation. 
The preparation of precursors A or A’ is illustrated in Figure 32. 
Commercially available p-coumaric acid (B) or 4-methoxy-cinnamic acid 
(B’) were treated with sodium azide, triphenylphosphine, and 
trichloroacetonitrile in acetonitrile118  to give the corresponding 
intermediate acyl azide derivatives C or C’. 
The subsequent Curtius rearrangement of C or C’ in toluene at 68°C 
overnight119  led to the isocyanates A or A', respectively, which were 
freshly used, due to their unstability. 
 
 
RO
COOH
B, R=H
B', R=Me
RO
CON3
C, R=H  81%
C', R=Me  78%
RO
NCO
A, R=H 78%
A', R=Me 79%
NaN3-Cl3CCN
PPh3
CH3CN
r.t / 2h
Toluene
68°C/overnight
 
 
Figure 32. Synthesis of Isocyanates precursors parazoanthine A and its O-Me derivative. 
 
In the coupling reaction (Figure 30) the obtained yields were quite low if 
compared to those reported by Stilz et al.117 This was probably due to the 
less nucleophilic reactivity of the isocyanate nitrogen atom being 
conjugated to the double bond. However, with the aim at improving the 
yields, different experimental conditions in the coupling step were used; 
in particular, the temperature was varied in the range of 20–60°C, distinct 
                                                          
118  Kim, J.G.& Jang, D.O., Synlett, 2008, p.2072-2074 
119 Marinescu, L.& Thinggaard, J.& Thomsen, I.B.& Bols, M., J. Org. Chem., vol. 68, 2003, p.9453-9455 
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solvents including DMF, DMSO, and THF were used, and N-
ethylmorpholine was added in the range of 1–3 equiv. 
The compounds 1 and 2 were thus obtained in the best experimental 
conditions with a yield of 11% and 10%, carrying out the reaction at room 
temperature, in DMF, and with 1.2 equivalents of N-ethylmorpholine. 
Finally, under these reaction conditions the chirality of the C-5 was 
preserved. 
By an accurate spectral analysis (1H-NMR, 13C-NMR, 1H-1H-COSY, HSQC, 
HMBC and HRESIMS) of synthetic parazoanthine A (1), it has highlighted 
an exact match with the data reported in the literature related to those of 
the natural compound.120  
The O-methyl ether derivative of parazoanthine A (2) showed 
spectroscopic data (1H-NMR and 13C-NMR) similar to parazoanthine A with 
the only difference due to the presence of the methoxyl on the aromatic 
ring. 
  
                                                          
120 Nadja Cachet, Gregory Genta-Jouve, Erik L. Regalado, RedouaneMokrini, Philippe Amade, Gerald 
Culioli, and Olivier P. Thomas. J.Nat.Prod. 2009, 72, 1612-1615. 
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 Parazoanthine-B, Parazoanthine-C and 18-deoxy-4.2
parazoanthine B synthesis 121 
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NH
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4: R = OCH3
5: R = H
13
14 5
6
 
 
Figure 33. Structure of parazoanthine B (3), parazoanthine C (4) 
and 18-deoxy-parazoanthine B (5). 
 
Within the natural class of parazoanthines other members, characterized 
by the presence of a Z-5,6 double bond (Figure 33) as the parazoanthine B 
(3) and C (4), are present; this double bond significantly complicates the 
synthetic strategy deviating from that used for the preparation of 
parazoanthine A. 
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Figure 34. Unsuitable synthetic approach for parazoanthine B. 
                                                          
121 Tinto Francesco; Dario Pagano; Emiliano Manzo. Tetrahedron  2015, 71, 4379–4384 
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In fact the coupling between the 2,3 dehydro-arginine methyl ester and 
isocyanate with N-ethylmorpholine in DMF (Figure 34), has not led to the 
desired parazoanthine B even varying the temperature, solvents and other 
experimental conditions, probably due to the lower nucleophilicity of the 
nitrogen of the dehydro-arginine methyl ester. 
The various attempts to introduce unsaturation on the parazoanthine A in 
positions 5 and 6 using common literature strategies didn’t lead significant 
results for the realization of parazoanthines characterized by the presence 
of the Z-5,6 double bond. All this has led us to the development of a 
different synthetic strategy for the preparation of these last 
parazoanthine derivatives. 
The key step of this new procedure is the coupling of a hydantoinic 
precursor Da/Db (Z/E stereoisomers mixture) with α-bromo-4’-methoxy-
acetophenone (E) (Figure 35), both prepared as illustrated in Scheme 1 
and 2, respectively. 
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Figure 35. Hydantoinic derivative Da and Db stereoisomers and 
 α-bromo-4’-methoxy-acetophenone (E). 
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In particular, the mixture of Z/E isomers Da/Db, was prepared by Horner – 
Wadsworth - Emmons reaction of the aldehyde (F), derived from of 3-
amino-1-propanol, with diethyl 2,4-dioxoimidazolidine-5-phosphonate (G), 
in turn prepared by bromination and subsequent substitution with 
triethylphosphite, according to literature conditions122 (Scheme 1).  
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Scheme 1. Preparation of synthetic precursors Da/Db. 
 
We obtained a mixture of Z/E isomers Da/Db in the ratio of 1.5/1 that was 
not easily detectable on the basis of NMR chemical shifts, but only by an 
                                                          
122 Meanwell, N.A.; Roth, H.R.; Smith, E.C.R.; Wedding, D.L.; Wright, J.J.K. J. Org. Chem. 1991, 56, 6897-
6904. 
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accurate analysis of the long-range (3JC-H) heteronuclear 13C-1H coupling 
constants that could distinguish them.123, 124 In particular for Da/Db the 
different configurations of the exocyclic double bond were evident by 
measuring 3JC4-H6 values (δH-6 5.73 and 5.56, δC-4 164.2 and 164.4, 3JC4-H6 
4.7 and 9.8 Hz for Da and Db respectively) by non-proton-decoupled J-
HMBC experiments (Figure  36) 115,116c. Compound Da revealed Z-geometry 
with the olefinic H-6 and the carbonyl C-4 in a cis-orientation, while Db 
showed E-geometry with H-6 and C-4 in a trans-orientation. 
Figure 36. Correlation H-6/C-4 J-HMBC for Da and Db 
On the other hand the precursor (E) was prepared by O-methylation and 
subsequent α-bromination of the commercially available 4’-hydroxy-
acetophenone with iodomethane in refluxing acetone and bromine in 
acetic acid (Scheme 2). 
 
                                                          
123 Cachet, N.; Genta-Jouve, G.; Regalado, E.L.; Mokrini, R.; Amade, P.; Culioli, G.; Thomas, O.P. J. Nat. 
Prod. 2009, 72, 1612-1615. 
124 (a) Jakše, R.; Rečnik, S.; Svete, J.; Golobič, A.; Golič, L.; Stanovnik, B. Tetrahedron 2001, 8395-8403; (b) 
Vergne, C.; Appenzeller, J.; Ratinaud, C.; Martin, M.-T.; Debitus, C.; Zaparucha, A.; Al-Mourabit, A. Org. 
Lett. 2008, 10, 493-496; (c) Meissner, A.; Sørensen, W. Magn. Reson. Chem. 2001, 39, 49-52. 
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O O
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4'-OMe-acetophenone,
 R=OCH3, 95%
acetophenone, R=H
R R
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M. R=H, 62%
O
HO
CH3I (9 equiv.) 
K2CO3 (5equiv.) 
Acetone
4'-OH-acetophenone
reflux 3h 50°C/overnight
 
 
Scheme 2. Preparation of synthetic precursors E and M. 
The coupling reaction between the prepared precursors Da/Db and E 
(Figure 37 and Scheme 3) consisted of the use of potassium carbonate and 
tetrabutylammonium bromide (TBAB) at 50 °C in anhydrous N,N-
dimethylformamide (DMF) addressing the N-imide bromine substitution 
to form compound H. (Figure 37) 
 
N
NH
O
O
R2
R1
N
NH
O
O
N
H
O BOC
O
Br
R
E Da/Db
R
H
 
Figure 37. Coupling mechanism between Da/Db and E 
Compound H presented the 3,5-alkyl disubstituted hydantoinic moiety 
typical of parazoanthines with an exocyclic 5,6-double bond with the 
desired Z geometry. The E isomer product was revealed only in trace 
probably due to the thermal isomerization of the double bond as indicated 
by an analytical test in which a small amount of Z/E mixture Da/Db was 
stirred at 50 °C in DMF, showing a significant increase of the portion of the 
Z-isomer (Da). (Figure 38) 
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Figure 38. Equilibrium between Da/Db stirred at 50 °C in DMF 
Reduction with sodium borohydride of the coupling adduct H gave 
compound I, that was then converted into L via dehydration and Boc-
cleavage by two equivalents of p-toluenesulfonic acid (p-TsOH) at 110 °C 
in toluene (Scheme 3). 
Compound L displayed a trans-double bond (JH13-H14= 15.4 Hz) between 
carbon 13 and 14 of the parazoanthine skeleton and was subsequently 
guanylated by 3,5-dimethyl-1-pyrazolylformaminidium nitrate125 and N,N-
diisopropylethylamine (DIPEA) in anhydrous DMF to give parazoanthine C 
(4) and 18-deoxy-parazoanthine B (5) (Figure 39 and scheme 3).  
 
N
HN
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H2N
N
NH3C
NH2HN
CH3
L, L'
R
 
 
                                                          
125
 (a) Bernatowicz, M.S.; Wu, Y.; Matsueda, G.R. J. Org. Chem. 1992, 57, 2497-2502; (b) Manzo, E.; 
Pagano, D.; Carbone, M.; Ciavatta, M.L.; Gavagnin, M. Arkivoc 2012, IX, 220-228. 
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Figure 39. Guanidination mechanism 
 
Synthetic parazoanthine C showed spectroscopic data identical with those 
of the natural molecule126 and was also demethylated by boron tribromide 
in dichloromethane, to give parazoanthine B (3) (scheme 3). 
 
                                                          
126 Cachet, N.; Genta-Jouve, G.; Regalado, E.L.; Mokrini, R.; Amade, P.; Culioli, G.; Thomas, O.P. J. Nat. 
Prod. 2009, 72, 1612-1615. 
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Scheme 3. Synthetic approach to get parazoanthine B (3), parazoanthine C (4)  
and 18-deoxy-parazoanthine B (5). 
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 Synthetic analog of natural parazoanthines (Para-N) 4.3
The docking wise have directed to the synthesis of no-natural analogs that 
would have a greater steric hindrance in the aromatic moiety, and they 
left unchanged the guanidinic portion. 
For this reason it was decided to synthetize a modified parazoanthine B in 
which the terminal phenolic ring is replaced with a bulkier naphthalene. 
This change was made because the pocket of the CXCR4 receptor is able 
to accommodate large molecules, and the aromatic moiety is capable of 
binding with the π-stacking interaction to the receptor that are definitely 
more with a naphthalene. (Figure 40) 
 
 
Figure 40. Para-N (6) 
 
To synthesize this parazoanthine analog (para-N), we used the method 
designed for the parazoanthine B; even in this case the key step of the 
procedure is the coupling of the hydantoinic derivatives Da/Db with α-
bromo-1-acetonaphthone (N), prepared as illustrated in Figure 41. 
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O O
Br
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10 min. / r.t.
CH3COOH
1-Acetonaphthone ( N ) 83%  
Figure 41. Alfa bromination of 1-acetonaphthone to obtain N 
The precursor N was synthesized starting from '1-acetonaphthone, 
reacted with bromine in acetic acid for 10 minutes at room temperature. 
The compound N reacted with the synthon Da/Db, previously synthesized 
(according to the method described in Scheme 1) to obtain the 
intermediate O. The reduction with NaBH4, and subsequent dehydration 
with p-TsOH in toluene at 110 ° C / 1h led to the intermediate Q. Finally 
we got the PARA-N (6), by the guanidination of Q, using the guanidinating 
reagent 3,5-dimethyl-1-pyrazolylformaminidium nitrate in basic conditions 
(Scheme 4). 
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Scheme 4. Synthetic approach to get PARA-N (6) 
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Chapter V 
 
5 Pharmacological activity tests in vitro 
Pharmacological tests in vitro were performed using only synthetic 
parazoanthine A. 
 Parazoanthine A 5.1
a) Proliferation Tests 
Preliminarily, used to validate the model, we have demonstrated that 
CXCL12 (25nm) induces in cells GH4C1 a significant increase of DNA 
synthesis after 24 hours of treatment, in conditions of prolonged 
deprivation of growth factors contained in FBS (72h), using the BrdU 
incorporation test. This prolonged serum deprivation condition is 
necessary to suppress any residual activation of the CXCR4 receptor by 
CXCL12 present in the serum. (Figure 42) 
 
Figure 42. Control test CXCR4/CXCL12 
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Always using BrdU incorporation test, we tested the ability of 
Parazoantina A to reduce the proliferation induced by CXCL12; the GH4 
cells were pre-treated for 15 minutes with the test compound at various 
concentrations (5μM, 1 micron, 500nm, 100nM and 50nM) before adding 
CXCL12 at a concentration of 25nm. As is evident from the graph, the 
pretreatment with Parazoantina A is able to inhibit in a dose-dependent 
manner the proliferation induced by CXCL12 that reaches a statistically 
significant value to the dose of 1 µM (about -30%). The effect obtained 
shows a typical plot "U" with lower efficacy at the 5 µM dose. (Figure 43) 
 
Figure 43. Proliferation Test CXCL12/Parazonathine A 
 
b) Cytotoxicity MTT assay 
To exclude non-specific cytotoxic effects of Parazoantina A, we performed 
a series of experiments of direct cytotoxicity by MTT assay in the absence 
of stimulation by CXCL12. None of the tested doses and the various 
treatment times are not significant toxic effects. This confirms that the 
inhibitory effect seen in the cell proliferation test was specifically 
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dependent of the antagonistic action of the molecule on CXCL12 activity 
and therefore by acting at the level of CXCR4. (Figure 44) 
 
 
Figure 44. Results of MTT tests; parazoanthine A haven’t non-specific cytotoxicity effect in all 
doses tested. 
 
Then we evaluated the effects Parazoanthine A on one of the intracellular 
pathways activated by CXCR4; in particular, we have considered the 
effects on the phosphorylation / activation of ERK1 / 2 induced by CXCL12 
by Western Blot. (Figure 46) The cells were pretreated with the compound 
at various concentrations (5uM, 1uM, 500nm, 100nM and 50nM) for 15 
minutes and subsequently stimulated with the chemokine 10 minutes at 
the concentration of 25nm. As can be observed, Parazoanthine A is able to 
inhibit the phosphorylation of ERK1 / 2 in the presence of CXCL12 at all 
concentrations tested. 
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Figure 45. Western Blot 
 
Preliminary biological assays on CXCR4 carried on Parazoanthine-A 
confirm the in silico results, whereas in vitro experiments are currently 
ongoing on Parazoanthine-B and its derivatives, in order to evaluate 
the effects of either substituents on aryl group or the bulkiness of the 
aromatic system on the biological activity for this class of molecules. 
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Chapter VI 
 
6 Conclusion 
 
The natural alkaloids characterized by the presence of the hydantoinic 
heterocycles have always awakened great interest in the scientific 
community not only for the interesting pharmacological activities, but also 
for their enormous applicative potential. In this context, the possibility of 
obtaining, by means of chemical synthesis methodologies, pure amounts 
of natural and no-natural analogs, opens the way to more extensive 
studies of structure-activity relationship, as well as the possibility to 
undertake any in vivo experimentation which in fact require amounts of 
substances not usually found in nature. In this regard we have been 
synthesized some representative guanidine alkaloids with hydantoinic 
core of the parazoanthines family, isolated and characterized previously 
by the anemone Parazoanthus axinellae. 
 In particular the first synthesis of parazoanthina A (1) and its 
analogue-O-methyl derivative127 (2), was carried out according to the 
known method of Stilz et al128,  finalized to the preparation of variously 
substituted hydantoinic nucleus; the key reaction resulted to be the 
coupling between the L-arginine methyl ester dihydrochloride and a 
feniletilen-isocyanate (A or A’); common sequence of reactions, including 
a keto-reduction with sodium borohydride, dehydration with p-TsOH and 
                                                          
127 Manzo E., Pagano D., Nuzzo G., Gavagnin M. and Ciavatta M.L:,  TetrahedronLetters 2012, 
53(52),7083–7084. 
128 Stilz, H.U.; Guba, W.; Jablonka, B.; Just, M.; Klingler, O.; Konig, W.; Wehner, V.; Zoller, G. J. Med. 
Chem. 2001, 44, 1158-1176. 
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final guanidination with an appropriate guanidination reagent led to 
target compound. This synthetic strategy might open the way for the 
preparation of other structural analogues (Scheme 5) and therefore 
permitting further structure-activity relationship studies aimed to increase 
the pharmacological potential of parazoanthines. 
 
 
 
 
        
Scheme 5. General synthetic strategy for derivatives parazoanthines 
 
We have also successfully synthesized the parazoanthine B,129 natural 
representative of parazoanthine with exocyclic Z-5,6-double bond. In this 
case the synthesis includes a first coupling reaction between a hydantoinic 
derivative (isomers mixture Da/Db) and the α-bromo-acetophenone, 
obtaining the 3,5-alkyl disubstituted hydantoinic moiety typical of 
parazoanthines with an exocyclic 5,6-double bond characterized by the 
desired Z geometry (H), which by subsequent reduction with sodium 
borohydride, dehydration, BOC-deprotection and final guanidination, led 
to desired parazoanthines B and C. Even in this case this synthetic 
approach may open the way to the realization of natural and no-natural 
analogues of parazoanthines with Z-5,6 double bond and other derivatives 
                                                          
129 Tinto Francesco; Dario Pagano; Emiliano Manzo. Tetrahedron  2015, 71, 4379–4384 
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that may differ in the length of the alkyl chain and / or in the type of 
substitution on the phenyl (Scheme 6). 
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Schema 6. General scheme for the preparation of analogues of parazoanthine with the Z-5,6 
double bond. 
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Chapter VII 
7 General experimental procedures 
All synthetic products and intermediates structures were assigned using 
1H, 13C, COSY, HSQC, HMBC NMR spectra. 
1H, 13C and 2D NMR spectra were acquired by the NMR Service of the 
Institute of Biomolecular Chemistry of the National Council of Research 
(ICB-CNR) and recorded on a Bruker DRX-600 spectrometer, equipped 
with a TCI CryoProbe™, fitted with a gradient along the Z-axis and on 
Bruker instruments at 400 and/or 300 MHz.  
Samples for NMR spectroscopic analysis were dissolved in the appropriate 
solvent; spectra in CDCl3 (1H,13C): 7.26, 77.0 ppm; CD3OD (1H,13C): 3.34, 
49.0 ppm. HRESIMS were performed on a Micromass Q-TOF MicroTM 
coupled with a HPLC Waters Alliance 2695. TLC plates (Kieselgel 60 F254) 
and silica gel powder (Kieselgel 60, 0.063-0.200 mm) were from Merck. 
All the reagents and solvents were purchased from Sigma-Aldrich and 
used without any further purification. 
 Procedures for the synthesis of parazoanthine A (1) and its 7.1
O-Me-analog (2) and spectral data of the synthetic 
intermediates. 
Compound C: p-coumaric acid (B) (0.5 g, 3.10 mmol), triphenylphosphine 
(1.62 g, 6.20 mmol) and sodium azide (0.24 g, 3.70 mmol) were dissolved 
in anhydrous acetonitrile (6 mL) under argon; trichloroacetonitrile (0.886 
g, 6.20 mmol) was added dropwise at room temperature; the reaction 
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mixture was stirred for 1.5 h and evaporated under reduced pressure; the 
residue was purified by silica gel chromatography using a gradient of 
petroleum ether/ethyl acetate to give compound C (0.48 g, 2.98 mmol, 
81%) as a pale yellow oil; 1H-NMR (CDCl3, 400 MHz): δ 7.71 (1H, d, J= 16.1 
Hz), 7.43 (2H, d, J= 8.42 Hz), 6.87 (2H, d, J= 8.42 Hz), 6.28 (1H, d, J=16.1 
Hz); 13C-NMR (CDCl3, 75 MHz): δ 173.0 (C), 158.8 (C), 146.8 (CH), 130.6 
(CH), 116.3 (CH), 116.1 (CH);  HRESIMS m/z 212.0431 [M+Na]+ (calcd for 
C9H7N3O2Na, 212.0436). 
 
 
 
 
 
HO
CON3
1H-NMR compound C, CDCl3, 400 MHz 
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Compound C’: 4-Methoxy-cinnamic acid (B’) (0.6 g, 3.37 mmol), 
triphenylphosphine (1.62 g, 6.74 mmol) and sodium azide (0.24 g, 4.04 
mmol) were dissolved in anhydrous acetonitrile (6 mL) under argon; 
trichloroacetonitrile (0.964 g, 6.74 mmol) was added dropwise at room 
temperature; the reaction mixture was stirred for 1.5 h and was 
evaporated under reduced pressure; the residue was purified by silica gel 
chromatography using a gradient of petroleum ether/ethyl acetate to give 
compound C’ (0.46 g, 2.63 mmol, 78%) as a pale yellow oil; 1H-NMR 
(CDCl3, 400 MHz): δ 7.73 (1H, d, J= 16.1 Hz), 7.46 (2H, d, J= 8.42 Hz), 6.90 
(2H, d, J= 8.42 Hz), 6.31 (1H, d, J=16.1 Hz), 3.78 (3H, s, OCH3); 13C-NMR 
(CDCl3, 75 MHz): δ 173.1 (C), .160.1 (C), 146.9 (CH), 130.8 (CH), 116.3 (CH), 
116.1 (CH), 56.8 (OCH3); HRESIMS m/z 226.0596 [M+Na]+ (calcd for 
C10H9N3O2Na, 226.0592). 
 
MeO
CON3
 
      C’ 
Compound A: Compound C (0.48 g, 2.98 mmol) was dissolved in 
anhydrous toluene (5 mL) and added dropwise to hot anhydrous toluene 
(10 mL) and heated to 68°C overnight; afterward the toluene was 
evaporated under reduced pressure obtaining compound A (0.374 g, 2.32 
mmol, 78%) as a pale yellow oil; 1H-NMR (CDCl3, 400 MHz): δ 7.24 (2H, d, 
J= 8.7 Hz), 6.51 (1H, d, J=15.7 Hz),  6.86 (2H, d, J= 8.7 Hz), 6.44 (1H, d, J= 
15.7 Hz). 
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Compound A’: Compound C’ (0.46 g, 2.63 mmol) was dissolved in 
anhydrous toluene (5 mL) and added dropwise to hot anhydrous toluene 
(10 mL) and heated to 68°C overnight; afterward the toluene was 
evaporated under reduced pressure obtaining compound A’ (0.368 g, 2.10 
mmol, 79%) as a pale yellow oil; 1H-NMR (CD3CN, 400 MHz): δ 7.74 (1H, d, 
J=15.8 Hz), 7.59 (2H, d, J= 8.6 Hz), 6.92 (2H, d, J= 8.6 Hz), 6.43 (1H, d, J= 
15.8 Hz), 3.79 (3H, s, OCH3). 
  
Compound 1: at 0°C, N-ethylmorpholine (67 mL, 0.522 mmol) and 
compound A (70 mg, 0.435 mmol) were added to a solution of L-arginine 
methyl ester dihydrochloride (114 mg, 0.435 mmol) in DMF (2 mL). The 
reaction mixture was stirred at 0°C for 1h and at r.t. for 5h; under a stream 
of nitrogen, the residue was purified by silica gel chromatography using a 
chloroform/methanol gradient and further purified by HPLC RP-phase 
HO
N
C O
1H-NMR compound A, CDCl3, 400 MHz 
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(H2O-TFA 0.1%/MeOH, from 60/40 to 50/50 in 20 minutes, RP-amide 
semipreparative column, flow rate 2 mL/min) to give compound 1 (15 mg, 
0.0521 mmol, 11%) as a pale yellow oil; [α]D - 7.4  (c 0.2, CH3OH); UV 
(MeOH) λmax (log e) 267 (3.85); IR (film) νmax 3362, 2948, 2920, 2853, 1716, 
1660, 160 cm-1; 1H NMR and 13C NMR of compound 1 were identical to 
those of natural parazoanthine A;130 HRMS-ESI: m/z [M + H]+ calcd for 
C15H20N5O3: 318.1561; found: 318.1564. 
 
 
 
 
   
                                                          
130 Nadja Cachet, Gregory Genta-Jouve, Erik L. Regalado, RedouaneMokrini, Philippe Amade, Gerald 
Culioli, and Olivier P. Thomas. J.Nat.Prod. 2009, 72, 1612-1615. 
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Compound 2: at 0°C, N-ethylmorpholine (62 µL, 0.480 mmol) and 
compound A’ (70 mg, 0.400 mmol) were added to a solution of L-arginine 
methyl ester dihydrochloride (105 mg, 0.435 mmol) in DMF (2 mL). The 
reaction mixture was stirred at 0°C for 1h and at r.t. for 5h; after 
evaporation under a stream of nitrogen, the residue was purified by silica 
gel chromatography using a chloroform/methanol gradient and further 
purified by HPLC RP-phase (H2O-TFA 0.1%/MeOH, from 60/40 to 50/50 in 
20 minutes, RP-amide semipreparative column, flow rate 2 mL/min) to 
give compound 2 (14 mg, 0.0439 mmol, 10%) as a pale yellow oil; UV 
(MeOH) λmax (log e) 261 (4.50); IR (film) νmax 3359, 2945, 2929, 1714, 1668, 
1623 cm-1; 1H NMR (CD3OD, 400 and 600 MHz): δ 7.48 (1H, d, J= 15.0 Hz, 
H-13), 7.37 (2H, d, J = 8.0 Hz, H-16 and H-20), 7.03 (1H, d, J=15.0 Hz, H-14), 
6.92 (2H, d, J= 8.0 Hz, H-17 and H-19), 3.78 (3H, s, OMe), 4.20 (1H, t, J = 
5.0 Hz, H-5), 3.26 (2H, t, J= 7.0 Hz, H2-8), 1.96-1.88 (1H, m, H-6a), 1.84-1.78 
(1H, m, H-6b), 1.79-1.71 (1H, m, H-7a), 1.69-1.62 (1H, m, H-7b); 13C NMR 
(CD3OD, 75 MHz): δ 174.2 (C, C-4), 163.1 (C, C-18), 162.0 (C, C-10), 157.2 
(C, C-2), 129.6 (C, C-15), 128.2 (CH, C-16 and C-20), 121.4 (CH, C-14), 117.1 
(CH, C-13), 115.1 (CH, C-17 and C-19), 56.9 (CH3, OMe), 55.7 (CH, C-5), 41.9 
(CH2, C-8), 29.7 (CH2, C-6), 24.9 (CH2, C-7); HRMS-ESI: m/z [M + H]+ calcd 
for C16H22N5O3: 332.3696; found: 332.3691. 
MeO
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 Synthetic procedure Parazoanthina B 7.2
Compound F: (Boc)2O (0.873 g, 4.0 mmol) and iodine (0.102 g, 0.4 mmol) 
were added to 3-amino-1-propanol (313 mL, 4.0 mmol) and the mixture 
was stirred for 2.5 h at room temperature; after portioning between 
sodium thiosulfate (6.0 g) and sodium bicarbonate (10.0 g) water solution 
(100 mL) and diethylether (200 mL), the organic phase was evaporated to 
give N-tert-butoxycarbonyl-amino-1-propanol (0.644 g, 3.9 mmol, 98%) 
that was oxidized with Dess-Martin reagent (2.80 g, 6.6 mmol) in 
dichloromethane (34 mL) overnight at room temperature; the mixture was 
partitioned between sodium thiosulfate (9.0 g) and sodium biocarbonate 
(10.0 g) water solution (100 mL) and dichloromethane (100 mL); the water 
was extracted with dichloromethane (100 mL) three times; the organic 
phase was evaporated and purified by silica gel chromatography using a 
gradient of n-hexane and ethyl acetate to give F (0.433 g, 2.5 mmol, 65%): 
colorless oil; 1H-NMR (400 MHz, CDCl3): δ 9.65 (1H, bs, H-1), 3.27 (2H, bq, 
J= 6.2 Hz, H2-3), 2.55 (2H, t, J= 5.9 Hz, H2-2), 1.40-1.22 (9H, s, Boc methyls); 
HRESIMS m/z 196.0953 [M+Na]+ (calcd for C8H15NNaO3, 196.0950).13 
 
Compound G: Hydantoin (2.000 g, 20.0 mmol), was dissolved in glacial 
acetic acid (8 mL) and heated at 85 °C; a small amount of bromine (0.120 
mL) was added and after 1 h and when the red color disappeared more 
bromine (1.08 mL) was added dropwise. After 30 min the mixture was 
cooled to 0 °C and triethyl phosphite (3.300 g, 28.0 mmol) was added; the 
mixture was heated at room temperature, stirred for 1.5 h and 
evaporated. The residue was crystallized in diethylether to give G (2.55 g, 
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10.8 mmol, 54%): white solid; NMR data was identical to those reported in 
the literature.10 
 
Compound  (Da/Db): Compound G (0.212 g, 0.9 mmol) was dissolved in an 
ethanolic solution (10 mL) of sodium ethoxide (74 mg, 1.08 mmol); 
compound F (0.130 g, 0.75 mmol) was added and the reaction was stirred 
at room temperature for 1.5 h; the mixture was evaporated and purified 
by silica gel chromatography using a chloroform/methanol gradient to give 
compound Da/Db as Z/E isomers mixture in the ratio 1.5/1.0 (0.161 g, 
0.63 mmol, 84%): pale yellow oil; Rf (chloroform/methanol 8/2) = 0.72; IR 
(film) νmax 3311, 2921, 2901, 2845, 1680, 1620 cm-1; 1H-NMR (400 MHz, 
CDCl3): δ 5.73 (1H, t, J= 8.4 Hz, H-3, Z form), 5.56 (1H, t, J= 8.1 Hz, H-3, E 
form), 3.23-3.14 (2H, m, H2-1, Z and E forms), 2.79 (2H, m, H2-2, E form), 
2.35 (2H, m, H2-2, Z form), 1.52-1.23 (9H, s, Boc methyls); 13C NMR (CDCl3): 
δ 164.4 (C, C-4’, E form), 164.2 (C, C-4’, Z form), 156.4 (C, Boc), 131.4 (C, C-
5’, Z form), 129.8 (C, C-5’, E form), 116.7 (CH, C-3, E form), 110.5 (CH, C-3, 
Z form), 79.7 (C, Boc), 39.7 (CH2, C-1, Z and E form), 28.4 (CH3, Boc), 27.2 
(CH2, C-2, Z form), 26.5 (CH2, C-2, E form); HRESIMS m/z 278.1112 [M+Na]+ 
(calcd for C11H17N3NaO4, 278.1117).  
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HSQC, compound Da/Db, CDCl3, 400 MHz 
1H-NMR compound Da/Db, CDCl3, 400 MHz 
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4’-OMe-acetophenone: 4’-OH-acetophenone (1 g, 0.0074 mol) was 
dissolved in acetone (750 mL) with potassium carbonate (5.1 g, 0.037 
mol); the mixture was refluxed for 15 min and iodomethane (9.6 g, 0.066 
mol) was added; the reaction was refluxed for 3 h, filtered, evaporated 
and purified by silica gel chromatography using a gradient of petroleum 
ether and diethylether to give 4’-OMe-acetophenone (1.6 g, 0.007 mmol, 
95%):colorless oil; 1H-NMR (400 MHz, CDCl3): δ 7.94 (2H, d, J= 8.1 Hz, H-2’, 
H-6’), 6.94 (2H, d, J= 8.1 Hz, H-3’, H-5’), 3.86 (3H, OMe), 2.54 (3H, s, H3-1); 
13C NMR (CDCl3): δ 198.4 (C), 165.0 (C), 129.4 (2 CH), 127.4 (C), 112.3 (2 
CH), 55.9 (OCH3), 23.4 (CH3). 
 
Compound E: 4’-OMe-acetophenone (1.04 g, 0.0066 mol) was dissolved in 
glacial acetic acid (7 mL); the temperature was increased at 50 °C and 
bromine (0.344 mL, 0.0066 mol) was added; the reaction was stirred 
overnight at 50 °C, evaporated and partitioned between a saturated 
sodium bicarbonate water solution (100 mL) and diethylether (100 mL); 
the organic phase was purified by silica gel chromatography using a 
gradient of petroleum ether and diethylether to give E (0.866 g, 0.0038 
mol, 57%): colorless oil; 1H-NMR (400 MHz, CDCl3): δ 7.95 (2H, d, J = 8.7 
Hz, H-2’, H-6’), 6.94 (2H, d, J = 8.7 Hz, H-3’, H-5’), 4.38 (2H, bs, H2-1), 3.86 
(3H, OMe). 
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Compound H: Compound Da/Db (61 mg, 0.239 mmol) was dissolved in 
anhydrous DMF (2.5 mL); potassium carbonate (34 mg, 0.239 mmol) and 
TBAB (2 mg) were added; the mixture was heated at 50 °C under argon 
atmosphere and compound E (65 mg, 0.287 mmol) was added after 15-30 
min; after 2 h the reaction was evaporated and purified by silica gel 
chromatography using a gradient of n-hexane and dichloromethane to 
give compound H (35 mg, 0.088 mmol, 37%): pale yellow oil; Rf 
(chloroform/methanol 95/5) = 0.35; IR (film) νmax 3315, 2921, 2901, 2845, 
1719, 1626 cm-1; 1H-NMR (400 MHz, CDCl3): δ 7.95 (2H, d, J= 8.7 Hz, H-16, 
H-20), 6.96 (2H, d, J= 8.7 Hz, H-17, H-19), 5.87 (1H, bt, J= 8.0 Hz, H-6), 4.95 
(2H, bs, H2-13), 3.90 (3H, s, OCH3), 3.22 (2H, bq, J= 6.6 Hz, H2-8), 2.44 (2H, 
m, H2-7), 1.57-1.36 (9H, s, Boc methyls); 13C NMR (CDCl3): δ 189.0 (C, C-14), 
162.4 (C, C-4), 164.1 (C, C-18), 156.2 (C, Boc), 153.8 (C, C-2), 131.2 (C, C-5), 
130.0 (CH, C-16 and C-20), 129.7 (C, C-15), 115.2 (CH, C-17 and C-19), 
111.0 (CH, C-6), 80.2 (C, Boc), 54.9 (CH3, OMe), 43.4 (CH, C-13), 39.9 (CH2, 
1H-NMR compound E, CDCl3, 400 MHz 
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C-8), 29.4, 29.0, 28.6 (CH3, Boc methyls), 29.1 (CH2, C-7); HRESIMS m/z 
426.1644 [M+Na]+ (calcd for C20H25N3NaO6, 426.1641). 
 
 
 
 
1H-NMR compound H, CDCl3,400 MHz 
HSQC compound H, CDCl3, 400 MHz 
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Compound I: Compound H (35 mg, 0.088 mmol) was dissolved in ethanol 
(3 mL) and sodium borohydride (4 mg, 0.105 mmol) was added; the 
mixture was stirred for 1 h at room temperature and after addition of 
some drops of water was partitioned between water (20 mL) and 
ethylacetate (20 mL); the organic phase was evaporated to get I (34 mg, 
0.084 mmol, 95%): pale yellow oil; Rf (chloroform/methanol 95/5) = 0.30; 
IR (film) νmax 3331, 2920, 2915, 2855, 1715, 1611 cm-1; 1H-NMR (400 MHz, 
CDCl3): δ 7.34 (2H, d, J= 7.7 Hz, H-16, H-20), 6.88 (2H, d, J= 7.7 Hz, H-17, H-
19), 5.85 (1H, t, J= 7.3 Hz, H-6), 4.97 (1H, bd, J= 6.5 Hz, H-14), 3.82 (2H, m, 
H2-13), 3.81 (3H, s, OCH3), 3.20 (2H, m, H2-8), 2.42 (2H, m, H2-7), 1.47-1.34 
(9H, s, Boc methyls); 13C NMR (CDCl3): δ 162.9 (C, C-4), 159.1 (C, C-18), 
156.3 (C, Boc), 156.1 (C, C-2), 132.8 (C, C-15), 130.1 (C, C-5), 127.5 (CH, C-
16 and C-20), 115.2 (CH, C-17 and C-19), 111.8 (CH, C-6), 80.1 (C, Boc), 
73.4 (CH, C-14), 54.9 (CH3, OMe), 44.5 (CH, C-13), 39.8 (CH2, C-8), 29.8, 
29.2, 28.6 (CH3, Boc methyls), 29.0 (CH2, C-7); HRESIMS m/z 428.1794 
[M+Na]+ (calcd for C20H27N3NaO6, 428.1798).  
 
1H-NMR compound I, CDCl3,400 MHz 
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Compound L: Compound I (34 mg, 0.084 mmol) was dissolved in toluene 
(3 mL) with monohydrated p-toluensulfonic acid (32 mg, 0.168 mmol); the 
mixture was heated at 110 °C for 1 h, evaporated and purified twice by 
silica gel chromatography using a gradient of chloroform and methanol to 
give L (11.7 mg, 0.041 mmol, 49%): pale yellow oil; Rf 
(chloroform/methanol 6/4) = 0.50; IR (film) νmax 3319, 2955, 2928, 2881, 
1719, 1626 cm-1; 1H-NMR (400 MHz, CD3OD): δ 7.50 (1H, d, J= 15.4 Hz, H-
14), 7.39 (2H, bd, J= 8.4 Hz, H-16, H-20), 7.08 (1H, d, J= 15.4 Hz, H-13), 6.93 
(2H, d, J= 8.4 Hz, H-17, H-19), 5.86 (1H, t, J= 7.6 Hz, H-6), 3.86 (3H, s, 
OCH3), 2.95 (2H, bt, J= 7.3 Hz, H2-8), 2.50 (2H, bq, J= 7.6 Hz, H2-7); 13C NMR 
(CD3OD): δ 160.6 (C, C-4), 159.2 (CH, C-18), 153.6 (C, C-2), 131.7 (C, C-5), 
127.7 (CH, C-16 and C-20), 126.4 (C, C-15), 120.4 (CH, C-14), 116.0 (CH, C-
13), 114.4 (CH, C-17, C-19), 110.5 (CH, C-6), 54.9 (CH3, OMe), 40.2 (CH2, C-
HSQC compound I, CDCl3,400 MHz 
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8), 28.3 (CH2, C-7); HRESIMS m/z 287.1275 [M+H]+ (calcd for C15H18N3O3, 
287.1270).  
 
 
 
1H-NMR compound L,CD3OD,400 
MHz 
HSQC compound L, CD3OD,400 MHz 
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Compound M: Acetophenone ( 0.466 mL, 0.004 mol) was dissolved in 
glacial acetic acid (4 mL) and heated at 50 °C; a small amount of bromine 
(0.040 mL) was added and after 1 h the rest of bromine (0.166 mL) was 
added; after overnight of stirring the mixture was evaporated and 
partitioned between a saturated sodium bicarbonate water solution (20 
mL) and diethylether (20 mL) that was evaporated and purified by silica 
gel chromatography using a gradient of light petroleum ether/diethylether 
to give compound M (0.494 g, 2.48 mmol, 62%): pale yellow oil; 1H-NMR 
(400 MHz, CDCl3): δ 7.97 (2H, d, J= 8.1 Hz, H-2’, H-6’), 7.59 (1H, bt, J= 7.6 
Hz, H-4’), 7.48 (2H, t, J= 8.1 Hz, H-3’, H-5’), 4.45 (2H, bs, H2-1). 
 
 
 
 
 
1H-NMR compound M, CDCl3,400 MHz 
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Compound H’: Compound Da/Db (61 mg, 0.239 mmol) was dissolved in 
anhydrous DMF (2.5 mL), potassium carbonate (34 mg, 0.239 mmol) and 
TBAB (2 mg) were added; the mixture was heated at 50 °C and compound 
M (58 mg, 0.287 mmol) was added; after 2h the reaction was evaporated 
and purified by silica gel chromatography using a gradient of n-hexane and 
dichloromethane to give compound H’ (30 mg, 0.079 mmol, 33%): pale 
yellow oil; Rf (chloroform/methanol 95/5) = 0.80; IR (film) νmax 3350, 2918, 
2939, 2840, 1728, 1620 cm-1; 1H-NMR (400 MHz, CDCl3): δ 7.97 (2H, d, J= 
7.5 Hz, H-16, H-20), 7.62 (1H, bt, J = 7.7 Hz, H-18), 7.50 (2H, t, J = 7.5 Hz, H-
17, H-19), 5.88 (1H, t, J = 7.9 Hz, H-6), 4.99 (2H, bs, H2-13), 3.22 (2H, bq, J = 
6.4 Hz, H2-8), 2.44 (2H, m, H2-7), 1.53-1.35 (9H, s, Boc methyls); 13C NMR 
(CDCl3): δ 190.5 (C, C-14), 162.8 (C, C-4), 156.3 (C, Boc), 153.4 (C, C-2), 
131.1 (C, C-5), 134.1, 128.7, 127.8 (CH, aromatic), 110.3 (CH, C-6), 80.4 (C, 
Boc), 44.3 (CH, C-13), 39.8 (CH2, C-8), 28.7, 28.2, 27.9 (CH3, Boc methyls), 
27.1 (CH2, C-7); HRESIMS m/z 396.1531 [M+Na]+ (calcd for C19H23N3NaO5, 
396.1535).  
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1H-NMR compound H’, CDCl3,400 MHz 
HSQC compound H’, CDCl3,400 MHz 
 pag. 104 
 
Compound I’: Compound H’ (30 mg, 0.079 mmol) was dissolved in ethanol 
(3 mL) and sodium borohydride (3.6 mg, 0.095 mmol) was added; the 
mixture was stirred for 1 h at room temperature and after addition of 
some drops of water was partitioned between water (20 mL) and 
ethylacetate (20 mL); the organic phase was evaporated to give I’ (28 mg, 
0.076 mmol, 96%): pale yellow oil; Rf (chloroform/methanol 95/5) = 0.45; 
IR (film) νmax 3350, 2929, 2909, 2863, 1735, 1618 cm-1; 1H-NMR (400 MHz, 
CDCl3): δ 7.42 (2H, bd, J = 7.8 Hz, H-16, H-20), 7.35 (2H, bt, J = 7.8 Hz, H-17, 
H-19), 7.30 (1H, bt, J = 7.6 Hz, H-18), 5.85 (1H, t, J= 8.4 Hz, H-6), 5.01 (1H, 
dd, J = 2.7, 7.8 Hz, H-14), 3.86 (2H, m, H2-13), 3.20 (2H, bq, J = 6.1 Hz, H2-
8), 2.41 (2H, bq, J = 6.9 Hz, H2-7), 1.50-1.38 (9H, s, Boc methyls); 13C NMR 
(CDCl3): δ 162.8 (C, C-4), 156.8 (C, Boc), 156.2 (C, C-2), 140.8 (C, C-15), 
130.3 (C, C-5), 128.2, 127.5, 127.1 (CH, aromatic), 110.6 (CH, C-6), 80.5 (C, 
Boc), 73.3 (CH, C-14), 47.2 (CH, C-13), 40.4 (CH2, C-8), 28.7, 28.4, 27.5 (CH3, 
Boc methyls), 27.9 (CH2, C-7); HRESIMS m/z 398.1696 [M+Na]+ (calcd for 
C19H25N3NaO5, 398.1692). 
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1H-NMR compound I’, CDCl3,400 MHz 
HSQC compound I’, CDCl3,400 MHz 
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Compound L’: Compound I’ (28 mg, 0.076 mmol) was dissolved in toluene 
(3 mL) with monohydrated p-toluensulfonic acid (26 mg, 0.152 mmol); the 
mixture was heated at 110 °C for 1 h, evaporated and purified twice by 
silica gel chromatography using a gradient of dichloromethane and 
methanol to give L’ (8.7 mg, 0.034 mmol, 45%): pale yellow oil; Rf 
(chloroform/methanol 7/3) = 0.35; IR (film) νmax 3320, 2935, 2909, 2872, 
1716, 1620 cm-1; 1H-NMR (400 MHz, CD3OD): δ 7.67 (1H, d, J= 15.1 Hz, H-
14), 7.50 (2H, bd, J = 7.5 Hz, H-16, H-20), 7.38 (2H, bt, J = 7.5 Hz, H-17, H-
19), 7.27 (1H, bt, J = 7.6 Hz, H-18), 7.23 (1H, d, J= 15.1 Hz, H-13), 5.87 (1H, 
t, J = 7.6 Hz, H-6), 3.11 (2H, bt, J = 7.3 Hz, H2-8), 2.58 (2H, bq, J = 7.3 Hz, H2-
7); 13C NMR (CD3OD): δ 162.4 (C, C-4), 153.3 (C, C-2), 137.1 (C, C-15), 131.8 
(C, C-5), 128.5, 128.0, 127.3 (CH, aromatic), 120.7 (CH, C-14), 118.4 (CH, C-
13), 109.8 (CH, C-6), 40.1 (CH2, C-8), 26.3 (CH2, C-7); HRESIMS m/z 
257.1205 [M+H]+ (calcd for C14H16N3O2, 257.1200); HRESIMS m/z 280.2773 
[M+Na]+ (calcd for C14H15N3NaO2, 280.2776). 
 
1H-NMR compound L’, CD3OD,400 
MHz 
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18-deoxy-parazoanthine B (5): Compound L’ (8.7 mg, 0.034 mmol) was 
dissolved in anhydrous DMF (0.5 mL) with DIPEA (0.051 mmol) and 3,5-
dimethyl-1-pyrazolylformaminidium nitrate (0.010 g, 0.051 mmol); the 
mixture was stirred overnight at room temperature under argon 
atmosphere, evaporated and fractioned by silica gel chromatography 
using a gradient of chloroform and methanol and further purified by HPLC 
RP-phase (H2O-TFA 0.1%/MeOH, from 60/40 to 50/50 in 20 minutes, RP-
amide analytical column, flow rate 1 mL/min) to give 5 (6.3 mg, 0.021 
mmol, 62%): pale yellow oil; Rf (chloroform/methanol 6/4) = 0.30; IR (film) 
νmax 3340, 2948, 2929, 2852, 1723, 1648 cm-1; 1H-NMR (400 MHz, CD3OD): 
δ 7.58 (1H, d, J= 15.0 Hz, H-14), 7.46 (2H, d, J = 7.4 Hz, H-16, H-20), 7.37 
(2H, bt, J = 7.5 Hz, H-17, H-19), 7.28 (1H, bt, J = 7.4 Hz, H-18), 7.22 (1H, d, J 
= 15.0 Hz, H-13), 5.85 (1H, bt, J = 7.7 Hz, H-6), 3.41 (2H, bt, J = 7.0 Hz, H2-
HSQC compound L’, CD3OD, 400 MHz 
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8), 2.58 (2H, bq, J =7.0, H2-7); 13C NMR (CD3OD): δ 162.4 (C, C-4), 158.7 (C, 
C-10), 153.9 (C, C-2), 137.2 (C, C-15), 131.6 (C, C-5), 129.5 (CH, C-17 and C-
19), 129.0 (CH, C-18), 127.2 (CH, C-16 and C-20), 120.8 (CH, C-14), 119.0 
(CH, C-13), 110.8 (CH, C-6), 40.9 (CH2, C-8), 26.4 (CH2, C-7); HRESIMS m/z 
300.1465 [M+H]+ (calcd for C15H18N5O2, 300.1460). 
 
1H-NMR compound 5, CD3OD,400 MHz 
13C-NMR compound 5, CD3OD,400 MHz 
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Parazoanthine C (4): Compound L (11.7 mg, 0.041 mmol) was dissolved in 
anhydrous DMF (0.5 mL) with DIPEA (0.062 mmol) and 3,5-dimethyl-1-
pyrazolylformaminidium nitrate (0.012 g, 0.062 mmol); the mixture was 
stirred overnight at room temperature under argon atmosphere, 
evaporated, fractioned by silica gel chromatography using a gradient of 
chloroform and methanol and further purified by HPLC RP-phase (H2O-TFA 
0.1%/MeOH, from 60/40 to 50/50 in 20 minutes, RP-amide analytical 
column, flow rate 1 mL/min) to give parazoanthine C (4) (8.6 mg, 0.026 
mmol, 63%): pale yellow oil; Rf (chloroform/methanol 6/4) = 0.25; IR (film) 
νmax 3368, 2951, 2925, 2852, 1720, 1656 cm-1; 1H-NMR (400 MHz, CD3OD): 
δ 7.48 (1H, d, J = 14.8 Hz, H-14), 7.36 (2H, d, J = 8.3 Hz, H-16, H-20), 7.06 
(1H, d, J = 14.8 Hz, H-13), 6.91 (2H, d, J = 8.3 Hz, H-17, H-19), 5.83 (1H, bt, J 
= 7.8 Hz, H-6), 3.80 (3H, s, OMe), 3.38 (2H, bt, J = 7.0 Hz, H2-8), 2.54 (2H, 
bq, J =7.0, H2-7); 13C NMR (CD3OD): δ 163.0 (C, C-4), 161.0 (C, C-18), 158.9 
(C, C-10), 154.6 (C, C-2), 131.3 (C, C-5), 129.6 (C, C-15), 128.5 (CH, C-16 and 
C-20), 121.5 (CH, C-14), 117.0 (CH, C-13), 115.4 (CH, C-17 and C-19), 110.2 
(CH, C-6), 55.8 (CH3, OMe), 41.3 (CH2, C-8), 27.5 (CH2, C-7); HRESIMS m/z 
330.1571 [M+H]+ (calcd for C16H20N5O3, 330.1566). 
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1H-NMR compound 4, CD3OD,400 MHz 
13C-NMR compound 4, CD3OD,400 MHz 
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Parazoanthine B (3): Parazoanthine C (4) (8.6 mg, 0.026 mmol) was 
dissolved in 1 mL of anhydrous dichloromethane boron tribromide 
solution (0.3 M), prepared by diluting a more concentrated 
dichloromethane boron tribromide solution (1M); the mixture was stirred 
for 1 h at 40 °C under argon atmosphere, evaporated, stirred with 
methanol/water solution (1/1, 1.5 mL) for ten minutes, dried and purified 
twice by silica gel chromatography using a gradient of dichloromethane 
and methanol to give 3 (3.8 mg, 0.012 mmol, 46 %): pale yellow oil; IR 
(film) νmax 3347, 2956, 2928, 2857, 1716, 1671 cm-1; 1H-NMR (400 MHz, 
CD3OD): δ 7.43 (1H, d, J = 14.7 Hz, H-14), 7.27 (2H, d, J = 8.2 Hz, H-16, H-
20), 6.98 (1H, d, J = 14.7 Hz, H-13), 6.78 (2H, d, J = 8.2 Hz, H-17, H-19), 5.80 
(1H, bt, J = 7.8 Hz, H-6), 3.35 (2H, bt, J = 7.1 Hz, H2-8), 2.54 (2H, bq, J = 7.0, 
H2-7); 13C NMR (CD3OD): δ 162.9 (C, C-4), 158.9 (C, C-10), 157.7 (C, C-18), 
154.5 (C, C-2), 131.3 (C, C-5), 128.5 (CH, C-16 and C-20), 128.4 (C, C-15), 
121.9 (CH, C-14), 116.7 (CH, C-17 and C-19), 116.2 (CH, C-13), 110.2 (CH, C-
6), 41.1 (CH2, C-8), 27.4 (CH2, C-7); HRESIMS m/z 316.1405 [M+H]+ (calcd 
for C15H18N5O3, 316.1410).  
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13C-NMR compound 3, CD3OD,400 MHz 
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 Synthesis of Para-N (6)  7.3
Compound N: 1-acetophenone (3.318 g, 0.0194 mol) was dissolved in 
glacial acetic acid (30 mL) at room temperature and bromine (1 mL, 
0.0390 mol) was added; the reaction was stirred 10 minutes at room 
temperature, evaporated and partitioned between a saturated sodium 
bicarbonate water solution (100 mL) and diethylether (100 mL); 
diethylether was dry with sodium sulfate to give N. (4 g, 0.0161 mol, 83% 
); 1H-NMR (400 MHz, CDCl3): δ 8.65 (1H, d, J = 8.7 Hz), 8.01 (1H, d, J = 8.2 
Hz), 7.88 (1H, d, J = 7.04 Hz partially overlapped), 7.85 (1H, d, J = 8.05 Hz 
partially overlapped), 7.62 (1H, t, J = 7.95 Hz), 7.55 (1H, t, J = 7.52 Hz), 7.47 
(1H, t, J = 7.62 Hz), 4.55 (2H, s); 13C NMR (CDCl3): δ 194.4 (C=O), 128.1 (C), 
133.6 (CH), 128.2 (CH), 127.8 (2CH), 125.5 (CH), 125.1 (CH), 123.1 (CH), 
32.0 (CH2); HRESIMS m/z 249.2701 [M+H]+ (calcd for C12H9BrO, 247.9837).  
  
OBr
1H-NMR compound N, CDCl3, 400 MHz 
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Compound  O: Compound Da/Db (150 mg, 0.587 mmol) was dissolved in 
anhydrous DMF (6.0 mL); potassium carbonate (121 mg, 0.876 mmol) and 
TBAB (14 mg) were added; the mixture was heated at 50 °C under argon 
atmosphere with molecular sieves and compound N (176 mg, 0.416 mmol) 
was added after 15-30 min; after 2 h the reaction was evaporated and 
purified by silica gel chromatography using a gradient of chloroform and 
methanol to give compound O (58 mg, 0.137 mmol, 33%); 1H-NMR (400 
MHz, CD3OD): δ 8.89 (1H, bs, NH), 8.67 (1H, d, J= 8.37 Hz), 8.04 (1H, d, J= 
8.2 Hz), 7.99 (1H, d, J= 7.27 Hz), 7.88 (1H, d, J= 7.95), 7.60-7.50 (2H, m, 
overlapped), 5.91 (1H, t, J= 8.23 Hz) 5.06 (2H, s), 3.22 (2H, m), 2.44 (2H, m) 
1.44 (9H, s, Boc methyls); 13C NMR (CD3OD): δ 194.4 (C), 162.4 (C), 156.2 
(C, Boc), 153.8 (C), 132.7 (CH), 127.6 (CH), 127.1 (CH) 124.9 (CH), 109.9 
(CH),  80.2 (C, Boc), 45.1 (CH2), 38.7 (CH2), 26.8 (CH2), 29.4, 29.0, 28.6 (CH3, 
Boc methyls),; HRESIMS m/z 423.1798 [M+Na]+ (calcd for C23H25N3O5, 
423.1794). 
O N
NH
O
O
N
H
O
O
1H-NMR compound O, CD3OD, 400 MHz 
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Compound P: Compound O (58 mg, 0.137 mmol) was dissolved in ethanol 
(4 mL) and sodium borohydride (6 mg, 0.156 mmol) was added; the 
mixture was stirred for 2 h at room temperature and after addition of 
some drops of water was partitioned between water (20 mL) and 
ethylacetate (20 mL); the organic phase was evaporated to give P (39 mg, 
0.091 mmol, 66%); 1H-NMR (400 MHz, CDCl3): δ 8.25 (1H,m), 8.06 (1H, m), 
7.88 – 7.70 (2H, m, overlapped), 7.58-7.32 (3H, m, overlapped), 5.86 (1H, 
m, overlapped) 5.79 (1H, epimer, m, overlapped), 5.62 (1H, epimer, m, 
overlapped), 3.98 – 3.64 (4H, m, overlapped) 1.44 (9H, s, Boc methyls); 13C 
NMR (CD3OD): δ 170.7 (C), 164.7 (C), 155.3 (C, Boc), 127.7 (CH), 127.0 (CH) 
124.7 (CH), 122.1 (CH), 110.1 (CH),  80.1 (C, Boc), 70.3 (CH, epimer), 68.2 
(CH, epimer)  59.1 (CH2), 47.6 (CH2), 44. (CH2), 27.7 (CH3, Boc methyls),; 
HRESIMS m/z 425.1948 [M+Na]+ (calcd for C23H27N3O5, 425.1951). 
 
 
HO N
NH
O
O
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Compound Q: Compound P (39 mg, 0.091 mmol) was dissolved in toluene 
(5 mL) with monohydrated p-toluensulfonic acid (70 mg, 0.37 mmol); the 
mixture was heated at 110 °C for 1 h, evaporated and partitioned between 
a saturated sodium bicarbonate water solution (100 mL) and chloroform 
(100 mL); chloroform was dry with sodium sulfate and purified further 
with silica gel chromatography using a gradient of chloroform and 
methanol to give Q (6 mg, 0.02 mmol, 22% ); 1H-NMR (400 MHz, CDCl3): δ 
8.33 (1H, d, J = 14.8 Hz), 8.14 (1H, d, J = 8.6 Hz), 7.90 (1H, d, J = 6.6 Hz), 
7.90 (1H, d, J = 8.3 Hz), 7.83 (1H, d, J = 7.0 Hz), 7.76 (1H, d, J = 7.9 Hz),  
7.65 – 7.41 (3H, m), 7.18 (1H, d, J = 14.5 Hz), 5.79 (1H, bt, J = 6.8 Hz), 2.87 
(2H, m), 2.44 (2H, bq, J = 6.1 Hz); HRESIMS m/z 308,1325 [M+H]+ (calcd for 
C18H17N3O2, 307,1321). 
 
N
NH
O
O
NH2
Q  
Compound 6: Compound Q (8.6 mg, 0.02 mmol) was dissolved in 
anhydrous DMF (1.0 mL) with DIPEA (6 µL, 0.03 mmol) and 3,5-dimethyl-1-
pyrazolylformaminidium nitrate (6 mg, 0.03 mmol); the mixture was 
stirred overnight at room temperature under argon atmosphere, 
evaporated, fractioned by silica gel chromatography using a gradient of 
chloroform and methanol and further purified by HPLC RP-phase (H2O-TFA 
0.1%/MeOH, from 60/40 to 50/50 in 20 minutes, RP-amide analytical 
column, flow rate 1 mL/min) to give compound 6 (3 mg, 0.008 mmol, 
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40%); 1H-NMR (400 MHz, CD3OD): δ 8.34 (1H, d, J = 14.2 Hz), 8.13 (1H, d, J 
= 8.5 Hz), 7.92 (1H, d, J = 6.6 Hz), 7.86 (1H, d, J = 8.3 Hz), 7.68 (1H, d, J = 
7.0 Hz), 7.61 – 7.44 (3H, m), 7.22 (1H, d, J = 14.6 Hz), 5.89 (1H, bt, J = 7.8 
Hz), 3.42 (2H, bt, J = 6.8 Hz), 2.60 (2H, bq, J = 7.0); 13C NMR (CD3OD): δ 
162.5 (C), 157.2 (C=NH), 153.8 (C),  125.4 (C), 129.4 (CH), 128.9 (CH), 126.7 
(CH), 124.5 (CH), 124.0 (CH), 119.9 (CH), 118.3 (CH), 110.1 (CH), 40.9 (CH2), 
27.3 (CH2); HRESIMS m/z 350,3277 [M+H]+ (calcd for C19H19N5O2, 
349,1539).  
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 Pharmacological assay 7.4
Cell line: In these experiments we used the GH4C1 cell line, immortalized 
cells derived from rat pituitary adenoma; we have previously shown that 
these cells express the receptor CXCR4 (but not CXCR7) and are sensitive 
to the proliferative chemokine CXCL12. These cells grow in terrain F10 
supplemented with 10% FBS. 
BrdU incorporation test: To study the modifications of the proliferative 
cell following treatment with Parazoantina, we used a quantitative 
colorimetric assay (BrdU ELISA kit, Roche) which is based on the 
bromodeoxyuridine (BrdU) ability to incorporate into the DNA, during the 
replicative phase. We seeded the cells in the basal soil and after 24h were 
put in a plot of serum free for a period of 72h. After this time, we pre-
treated cells 15 'with the test compound at various concentrations (5µM, 
1µM, 500nm, 100 nM and 50 nM) and later added CXCL12 25 nM for 24h. 
About twelve hours before the experimental time we BrdU added to each 
well to a final concentration of 10 µM. Subsequently the cells were fixed 
by exposure for 30 minutes to the alcoholic fixative (FixDenat) contained 
in the kit. After three washes of 5 minutes each with a wash solution 
provided in the kit, we incubated the cells for three minutes at room 
temperature, with Lumino / 4-Iodophenol, substrate of the enzyme 
peroxidase. The chemiluminescence was read in a spectrophotometer. 
Cytotoxicity MTT assay: This currency methodical cell vitality by 
measuring the activity of the mitochondrial dehydrogenase. We plating 
cells in medium containing serum and treated with the drug at different 
concentrations. The cells, and after 24,48,72 and 96 h of appropriate 
treatments, they were incubated 1h at 37 ° C with 3- (4,5-dimethylthiazol-
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2-yl) -2,5-diphenyltetrazolium (0.25mg / ml ). The mitochondria of viable 
cells convert the tetrazolium salt (water soluble and yellow) into blue 
insoluble formazan crystals; the crystals are then solubilized in dimethyl-
sulfoxide (DMSO) and the color intensity is quantified using a 
spectrophotometer (570 nm). The quantity of formazan and thus the 
intensity of the blue color is proportional to the viability of cells in culture. 
Western Blot: The cells deprived of serum for 72h have been pre-treated 
with the various concentrations Parazoantina (5µM, 1µM, 500nM, 100nM 
and 50nM) and subsequently stimulated with CXCL12 for 10 '. 
Subsequently, we washed the cells with PBS and lysed at 4 ° C in a solution 
containing 20mM Tris-HCL pH 7.4, 140mm NaCl, 2mM EDTA, 10% glycerol, 
1% NP-40, 1mM sodium ortovanadato, 1mM phenyl-methyl- sulfonyl-
fluoride (PMSF), 10mM NaF and a mixture of protease inhibitors ( 
"Complete", Roche). After centrifugation (10 'at 5000 rpm at 4 ° C) carried 
out to remove the nuclei, we calculated the amount of protein by the 
Bradford method (BioRad). Appropriate amount of protein (20 ug) of each 
sample were resuspended in a reducing buffer (2% SDS, 62.5 mM Tris pH 
6.8, 0:01% of Bromophenol Blue, 1:43 mM B-mercaptoethanol and 0.1% 
glycerol), denatured by boiling, separated by electrophoresis on 
polyacrylamide gel (10% SDS-PAGE) and transferred via the membrane of 
polyvinylidene difluoride (PVDF). The membranes were then incubated 
with the antibody directed against the phosphorylated form of ERK 1/2. 
Immunoreactivity was detected by a subsequent incubation with 
secondary antibody linked to peroxidase, followed by reaction of 
chemiluminescence. The same cell lysates were analyzed for the total 
expression by the tubulin protein, to check that each treatment contained 
the same amount of protein. 
 pag. 120 
 
 Computational Methods 7.5
Docking studies were performed with AutoDock 4.2131. Both the 
crystallographic structure of CXCR4 (PDB entry 3OE0) and the investigated 
ligands were processed with AutoDock Tools (ADT) package to merge non 
polar hydrogens, calculate Gasteiger charges and desolvation parameters, 
and select all rotatable ligand bonds as flexible. Grids for docking 
evaluation with a spacing of 0.375 Å and 70x70x50 points, centered in the 
ligand binding pocket, were generated using the program AutoGrid 4.2 
included in Autodock 4.2 distribution. Lamarckian Genetic Algorithm (LGA) 
was adopted to perform 100 docking runs with the following parameters: 
100 individuals in a population with a maximum of 15 million energy 
evaluations and a maximum of 37000 generations, followed by 300 
iterations of Solis and Wets local search. PARAZOANTHINE-CXCR4 
complexes were selected on the basis of binding energy and cluster 
population. The x-ray structure was cleaned of the fusion protein at the 
intracellular loop 3 (IL3) and completed in its not-resolved loop regions 
using MODELLER program version 9.15132 and the resulting complexes, 
after addition of all hydrogen atoms, underwent energy minimization with 
SANDER module of Amber14 package133 using the ff14SB version of 
AMBER force field for the protein and GAFF for the ligand. Ligand atomic 
                                                          
131 G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, et al., AutoDock4 and 
AutoDockTools4: Automated docking with selective receptor flexibility., J. Comput. Chem. 30 (2009) 
2785–91. doi:10.1002/jcc.21256. 
 
132 N. Eswar, B. Webb, M.A. Marti-Renom, M.S. Madhusudhan, D. Eramian, M.-Y. Shen, et al., 
Comparative protein structure modeling using Modeller., Curr. Protoc. Bioinformatics. Chapter 5 (2006) 
Unit 5.6. doi:10.1002/0471250953.bi0506s15. 
133 D.A. Case, V. Babin, J.T. Berryman, R.M. Betz, Q. Cai, D.S. Cerutti, T.E. Cheatham, III, T.A. Darden, R.E. 
Duke, H. Gohlke, A.W. Goetz, S. Gusarov, N. Homeyer, P. Janowski, J. Kaus, I. Kolossváry, A. Kovalenko, 
T.S. Lee, S. LeGrand, T. Luchko, R. Luo, B. Madej, K.M. Merz, F. Paesani, D.R. Roe, A. Roitberg, C. Sagui, R. 
Salomon-Ferrer, G. Seabra, C.L. Simmerling, W. Smith, J. Swails, R.C. Walker, J. Wang, R.M. Wolf, X. Wu 
and P.A. Kollman (2014), AMBER 14, University of California, San Francisco. 
http://ambermd.org/doc12/Amber14.pdf 
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charges were obtained with the RESP methodology134, according to the 
prescription for molecule parametrization in the GAFF force field. This 
latter requires an ab initio full geometry optimization at the Hartree-Fock 
level using the STO-3G basis set, followed by a single-point energy 
calculations on the optimized molecule at the RHF/6-31G* level. Ab initio 
calculations were performed with GAMESS program135. 
  
                                                          
134
 T. Fox, P.A. Kollman, Application of the RESP Methodology in the Parametrization of Organic 
Solvents, J. Phys. Chem. B. 102 (1998) 8070–8079. doi:10.1021/jp9717655. 
135
 Advances in electronic structure theory: GAMESS a decade later" M.S.Gordon, M.W.Schmidt pp. 
1167-1189, in "Theory and Applications of Computational Chemistry: the first forty years" C.E. Dykstra, 
G.Frenking, K.S.Kim, G.E.Scuseria (editors), Elsevier, Amsterdam, 2005. 
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